<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T08:55:06Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:3779727" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:3779727</identifier>
        <datestamp>2013-09-23</datestamp>
        <setSpec>jbc</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Biol Chem</journal-id>
              <journal-id journal-id-type="iso-abbrev">J. Biol. Chem</journal-id>
              <journal-id journal-id-type="hwp">jbc</journal-id>
              <journal-id journal-id-type="pmc">jbc</journal-id>
              <journal-id journal-id-type="publisher-id">JBC</journal-id>
              <journal-title-group>
                <journal-title>The Journal of Biological Chemistry</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0021-9258</issn>
              <issn pub-type="epub">1083-351X</issn>
              <publisher>
                <publisher-name>American Society for Biochemistry and Molecular Biology</publisher-name>
                <publisher-loc>9650 Rockville Pike, Bethesda, MD 20814, U.S.A.</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC3779727</article-id>
              <article-id pub-id-type="pmcid">PMC3779727</article-id>
              <article-id pub-id-type="pmc-uid">3779727</article-id>
              <article-id pub-id-type="pmid">23897810</article-id>
              <article-id pub-id-type="publisher-id">M113.484212</article-id>
              <article-id pub-id-type="doi">10.1074/jbc.M113.484212</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Immunology</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Soluble Ecto-5′-nucleotidase (5′-NT), Alkaline Phosphatase, and Adenosine Deaminase (ADA1) Activities in Neonatal Blood Favor Elevated Extracellular Adenosine<xref ref-type="fn" rid="FN1">*</xref>
<xref ref-type="fn" rid="FN2"><sup><inline-graphic xlink:href="sbox.jpg"/></sup></xref></article-title>
                <alt-title alt-title-type="short">Anti-inflammatory Purine Metabolism Profile in Newborn Blood</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pettengill</surname>
                    <given-names>Matthew</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>‡</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff3">
                    <sup>§</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Robson</surname>
                    <given-names>Simon</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">
                    <sup>§</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff2">
                    <sup>¶</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tresenriter</surname>
                    <given-names>Megan</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>‡</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Millán</surname>
                    <given-names>José Luis</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff4">
                    <sup>‖</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Usheva</surname>
                    <given-names>Anny</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">
                    <sup>§</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff2">
                    <sup>¶</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bingham</surname>
                    <given-names>Taiese</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>‡</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff3">
                    <sup>§</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Belderbos</surname>
                    <given-names>Mirjam</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff5">**</xref>
                  <xref ref-type="author-notes" rid="FN3">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bergelson</surname>
                    <given-names>Ilana</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>‡</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Burl</surname>
                    <given-names>Sarah</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff6">
                    <sup>‡‡</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff7">
                    <sup>§§</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="FN4">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kampmann</surname>
                    <given-names>Beate</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff6">
                    <sup>‡‡</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff7">
                    <sup>§§</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="FN4">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gelinas</surname>
                    <given-names>Laura</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff8">
                    <sup>¶¶</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="FN5">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kollmann</surname>
                    <given-names>Tobias</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff9">
                    <sup>‖‖</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="FN6">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bont</surname>
                    <given-names>Louis</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff5">**</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Levy</surname>
                    <given-names>Ofer</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>‡</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff3">
                    <sup>§</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor1">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <aff id="aff1">From the <label>‡</label>Department of Medicine, Division of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts 02115, </aff>
                <aff id="aff2">the <label>¶</label>Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, </aff>
                <aff id="aff3"><label>§</label>Harvard Medical School, Boston, Massachusetts 02115, </aff>
                <aff id="aff4">the <label>‖</label>Sanford Children's Health Research Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037, </aff>
                <aff id="aff5">the <label>**</label>Department of Pediatrics, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands, </aff>
                <aff id="aff6">the <label>‡‡</label>Vaccinology Theme Group, Medical Research Council Unit, Fajara, The Gambia, and </aff>
                <aff id="aff7">the <label>§§</label>Department of Pediatrics, Imperial College London, London W2 IPG, United Kingdom, and </aff>
                <aff id="aff8">the <label>¶¶</label>Experimental Medicine Program, Department of Medicine, and </aff>
                <aff id="aff9">the <label>‖‖</label>Division of Infectious and Immunologic Diseases, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1"><label>5</label> The laboratory of this author is supported in part by Bill and Melinda Gates Foundation Global Health Award OPPGH5284 and Grand Challenges Explorations Award OPP1035192. To whom correspondence should be addressed: <addr-line>Dept. of Medicine, Division of Infectious Diseases, Boston Children's Hospital, 300 Longwood Ave., Boston, MA 02115.</addr-line> Tel.: <phone>617-919-2904</phone>; Fax: <fax>617-730-0254</fax>; E-mail: <email>ofer.levy@childrens.harvard.edu</email>.</corresp>
                <fn fn-type="supported-by" id="FN3">
                  <label>1</label>
                  <p>Supported by a European Society for Pediatric Infectious Diseases travel grant.</p>
                </fn>
                <fn fn-type="supported-by" id="FN4">
                  <label>2</label>
                  <p>Supported by the Medical Research Council, United Kingdom.</p>
                </fn>
                <fn fn-type="other" id="FN5">
                  <label>3</label>
                  <p>Recipient of a Frederick Banting and Charles Best Canada Graduate Scholarship from the Canadian Institutes of Health Research.</p>
                </fn>
                <fn fn-type="supported-by" id="FN6">
                  <label>4</label>
                  <p>Supported in part by a Burroughs Wellcome Career Award in the Biomedical Sciences, a Michael Smith Foundation for Health Research Career Investigator Award, and the AllerGen NCE Grants 07-A1A and 07-B2B.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="ppub">
                <day>20</day>
                <month>9</month>
                <year>2013</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>29</day>
                <month>7</month>
                <year>2013</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>29</day>
                <month>7</month>
                <year>2013</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. -->
              <volume>288</volume>
              <issue>38</issue>
              <fpage>27315</fpage>
              <lpage>27326</lpage>
              <history>
                <date date-type="received">
                  <day>8</day>
                  <month>5</month>
                  <year>2013</year>
                </date>
                <date date-type="rev-recd">
                  <day>26</day>
                  <month>7</month>
                  <year>2013</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2013 by The American Society for Biochemistry and Molecular Biology, Inc.</copyright-statement>
                <copyright-year>2013</copyright-year>
                <license license-type="open-access">
                  <license-p><italic>Author's Choice</italic>—Final version full access.</license-p>
                  <license-p><ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution Unported License</ext-link> applies to Author Choice Articles</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zbc03813027315.pdf"/>
              <abstract abstract-type="teaser">
                <p><bold>Background:</bold> Newborns have elevated plasma adenosine levels, which may influence their immunological function.</p>
                <p><bold>Results:</bold> Compared with adults, newborns have elevated plasma 5′-NT and alkaline phosphatase activities and lower adenosine deaminase activity.</p>
                <p><bold>Conclusion:</bold> Soluble enzymes significantly influence extracellular purine metabolism in blood, and the levels of these enzymes in newborns promote elevated adenosine.</p>
                <p><bold>Significance:</bold> Higher adenosine generation in newborn blood may promote an anti-inflammatory immunological status.</p>
              </abstract>
              <abstract>
                <p>Extracellular adenosine, a key regulator of physiology and immune cell function that is found at elevated levels in neonatal blood, is generated by phosphohydrolysis of adenine nucleotides released from cells and catabolized by deamination to inosine. Generation of adenosine monophosphate (AMP) in blood is driven by cell-associated enzymes, whereas conversion of AMP to adenosine is largely mediated by soluble enzymes. The identities of the enzymes responsible for these activities in whole blood of neonates have been defined in this study and contrasted to adult blood. We demonstrate that soluble 5′-nucleotidase (5′-NT) and alkaline phosphatase (AP) mediate conversion of AMP to adenosine, whereas soluble adenosine deaminase (ADA) catabolizes adenosine to inosine. Newborn blood plasma demonstrates substantially higher adenosine-generating 5′-NT and AP activity and lower adenosine-metabolizing ADA activity than adult plasma. In addition to a role in soluble purine metabolism, abundant AP expressed on the surface of circulating neonatal neutrophils is the dominant AMPase on these cells. Plasma samples from infant observational cohorts reveal a relative plasma ADA deficiency at birth, followed by a gradual maturation of plasma ADA through infancy. The robust adenosine-generating capacity of neonates appears functionally relevant because supplementation with AMP inhibited whereas selective pharmacologic inhibition of 5′-NT enhanced Toll-like receptor-mediated TNF-α production in neonatal whole blood. Overall, we have characterized previously unrecognized age-dependent expression patterns of plasma purine-metabolizing enzymes that result in elevated plasma concentrations of anti-inflammatory adenosine in newborns. Targeted manipulation of purine-metabolizing enzymes may benefit this vulnerable population.</p>
              </abstract>
              <kwd-group>
                <kwd>Adenosine</kwd>
                <kwd>Adenosine Receptor</kwd>
                <kwd>ADP</kwd>
                <kwd>AMP</kwd>
                <kwd>ATP</kwd>
                <kwd>Immunology</kwd>
                <kwd>Infectious Diseases</kwd>
                <kwd>Innate Immunity</kwd>
                <kwd>Purine</kwd>
                <kwd>Purinergic Agonists</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source id="CS100">National Institutes of Health</funding-source>
                  <award-id rid="CS100">1R01AI100135-01</award-id>
                  <award-id rid="CS100">T32 HD055148</award-id>
                  <award-id rid="CS100">R01 HL094400</award-id>
                  <award-id rid="CS100">R21 CA164970</award-id>
                  <award-id rid="CS100">P01 HL087203</award-id>
                  <award-id rid="CS100">R01 DE012889</award-id>
                  <award-id rid="CS100">R01 AR053102</award-id>
                  <award-id rid="CS100">N01 AI50023</award-id>
                </award-group>
              </funding-group>
            </article-meta>
          </front>
          <body>
            <sec>
              <title>Introduction</title>
              <p>Purine signaling nucleotides and nucleosides, primarily adenosine triphosphate (ATP) and adenosine, are critical pathophysiologic mediators. In the context of immunity and inflammation, extracellular ATP (eATP)<xref ref-type="fn" rid="FN7"><sup>6</sup></xref> is important for T-cell activation (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>) and proliferation (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>), promoting neutrophil adhesion (to endothelial cells (<xref ref-type="bibr" rid="B5">5</xref>)) and degranulation (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>), reactive oxygen species production (<xref ref-type="bibr" rid="B8">8</xref>), and multiple other proinflammatory immune cell functions (<xref ref-type="bibr" rid="B9">9</xref>). Extracellular adenosine (eAdo) is primarily generated by the metabolism of eATP and has an opposing profile of immunoregulatory effects from the precursor molecule; eAdo inhibits neutrophil-endothelial adhesion (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>) and degranulation (<xref ref-type="bibr" rid="B12">12</xref>), reactive oxygen species production (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>), and macrophage production of proinflammatory/Th1-polarizing cytokines (IL-12p70, TNF-α) (<xref ref-type="bibr" rid="B9">9</xref>) as well as T-cell proliferation and effector functions (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>). eATP is primarily transported outside of cells by vesicular trafficking or secreted via pannexin-1 channels (<xref ref-type="bibr" rid="B17">17</xref>), where it can then stimulate P2 purinergic receptors and also serve as a source of eAdo through sequential dephosphorylation by several types of ectonucleotidases leading to P1 (Ado) receptor signaling (<xref ref-type="bibr" rid="B18">18</xref>). Thus, the enzymes involved in extracellular purine metabolism critically regulate whether eATP release results in largely P2 receptor-mediated proinflammatory sequelae or P1 receptor stimulation and an anti-inflammatory response.</p>
              <p>There are four families of ectonucleotidases (<xref ref-type="bibr" rid="B19">19</xref>): ENTPDs (including ENTPD1 (CD39); substrates ATP and ADP), ectonucleotide pyrophosphatase/phosphodiesterases (substrates ATP and ADP), alkaline phosphatases (APs; substrates ATP, ADP, and AMP), and ecto-5′-nucleotidase (5′-NT (CD73); substrate AMP). Additionally, it was recently shown that adenylate kinase (AK1) influences extracellular adenine nucleotide pools via transphosphorylation (<xref ref-type="bibr" rid="B20">20</xref>). 5′-NT and AP are both attached to the plasma membrane by a glycosylphosphatidylinositol anchor and are found in plasma, possibly as a consequence of glycosylphosphatidylinositol-specific phospholipase activity (<xref ref-type="bibr" rid="B21">21</xref>–<xref ref-type="bibr" rid="B24">24</xref>). Of note, eAdo can be taken up into cells via nucleoside transporters (<xref ref-type="bibr" rid="B25">25</xref>) or be metabolized by adenosine deaminase (primarily ADA1, whereas the product of another gene (<italic>CECR1</italic>), referred to as ADA2, has little activity near physiological concentrations of Ado), generating inosine. Extracellular ADA1 is found either soluble in fluids or cell-associated via binding to CD26 (<xref ref-type="bibr" rid="B26">26</xref>) or Ado receptors (<xref ref-type="bibr" rid="B27">27</xref>). Increased ectonucleotidase activity would both diminish eATP exposure and enhance eAdo production, shifting subsequent cellular responses to an anti-inflammatory profile. In addition, modified levels of ADA1 activity or cellular adenosine transport could promote eAdo retention. An ectopurine enzyme profile that favors the metabolism of eATP and production and retention of eAdo should then mediate dampening of inflammatory and Th1-polarizing immune responses.</p>
              <p>Innate immune responses in human newborns are distinct from those of adults (<xref ref-type="bibr" rid="B28">28</xref>), favoring higher production of Th2- and Th17-polarizing cytokines (<italic>e.g.</italic> IL-4 and IL-6) and diminished production of proinflammatory/Th1-polarizing cytokines (<italic>e.g.</italic> TNF-α and IL-12p70) in response to Toll-like receptor (TLR) agonists or whole microbes <italic>in vitro</italic> (<xref ref-type="bibr" rid="B29">29</xref>–<xref ref-type="bibr" rid="B31">31</xref>). Impaired neonatal production of key cytokines, such as TNF-α, may contribute to impaired mobilization and activation of phagocytes and to impaired vaccine responses (<xref ref-type="bibr" rid="B28">28</xref>). Interestingly, the polarized neonatal cytokine profile may be influenced by soluble factors in newborn plasma (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>), which contains significantly higher levels of eAdo than adult plasma (<xref ref-type="bibr" rid="B32">32</xref>). In the current study, we assessed whether the difference in eAdo in newborn blood was due to differential levels of blood ectoenzyme expression. We found that direct eAdo-generating enzymes and ADA activities in whole blood were primarily soluble, not cell- or microparticle-associated. Remarkably, newborn whole blood <italic>ex vivo</italic> generated more and metabolized less eAdo than adult blood from exogenous purine precursors (ADP or AMP), due primarily to elevated soluble 5′-NT and tissue-nonspecific alkaline phosphatase (TNAP)-mediated AMPase activity and lower soluble ADA1 activity, respectively.</p>
            </sec>
            <sec sec-type="materials|methods">
              <title>MATERIALS AND METHODS</title>
              <sec>
                <title/>
                <sec>
                  <title/>
                  <sec>
                    <title>Reagents</title>
                    <p>Adenosine 5′-(α,β-methylene)-diphosphate (APCP) was obtained from Sigma. EDTA and Hanks' buffered salt solution with (HBSS+) or without (HBSS−) calcium and magnesium were from Invitrogen. MLS-0038949 (<xref ref-type="bibr" rid="B34">34</xref>) was purchased from EMD Millipore (Billerica, MA). <italic>erythro</italic>-9-(2-Hydroxy-3-nonyl)adenine hydrochloride (EHNA) and 2,6-bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-<italic>d</italic>]pyrimidine (dipyridamole) were acquired from Tocris Cookson (Bristol, UK). Ficoll-Paque, Percoll, ammonium hydroxide, and 2-propanol were purchased from Fisher. 8-Aminoguanosine was obtained from Santa Cruz Biotechnology, Inc. Other reagents and sources are listed with assay descriptions.</p>
                  </sec>
                  <sec>
                    <title>Blood Collection</title>
                    <p>Peripheral blood was collected after informed consent from healthy adult volunteers according to Boston Children's Hospital Institutional Review Board-approved protocols (mean age 31.3 years), and newborn cord blood (mean gestational age 38.9 weeks) was collected immediately after elective cesarean section delivery (epidural anesthesia) of the placenta. Births to HIV-positive mothers were excluded. Human experimentation guidelines of the United States Department of Health and Human Services, the Brigham and Women's Hospital, Beth Israel Medical Center, and Boston Children's Hospital were observed, following protocols approved by the local institutional review boards. Number of repeats (<italic>n</italic>) indicates number of independent experiments. For primary human cells (or plasma), no subject was studied more than once in each of the different experiments. Blood was collected into syringes containing a final concentration of 20 units/ml heparin (Sagent Pharmaceuticals, Schaumberg, IL) and used within 2 h of collection.</p>
                  </sec>
                  <sec>
                    <title>Blood Plasma Collection from International Cohorts</title>
                    <p>Blood plasma was collected in a cross-sectional study (as described previously (<xref ref-type="bibr" rid="B35">35</xref>)) at birth and at 1, 2, 3, 4, 6, 9, and 12 months at the Medical Research Council Sukuta Health Centre in Fajara, The Gambia. Briefly, for every study subject, written informed consent of a parent/guardian was obtained. Children were excluded if they had any signs of intercurrent infection. Neonates were also excluded if they had a low birth weight (&lt;2.5 kg) or were a twin. Venous blood was collected into tubes containing heparin at 7.5 units/ml blood and centrifuged at 1500 rpm for 10 min, and plasma was removed and frozen for future analysis. A separate longitudinal study at birth and at 1 and 2 years of age from which plasma was obtained was approved by the Institutional Ethics Review Board at both the University of Washington and the University of British Columbia, and details of this cohort and subject recruitment have been described previously (<xref ref-type="bibr" rid="B36">36</xref>). Briefly, following written and informed consent, cord or peripheral blood was collected via sterile venipuncture into tubes containing 143 USP units of sodium heparin (Vacutainer Tubes, BD Biosciences). Blood was centrifuged at 1250 rpm for 10 min, and plasma was removed and frozen at −80 ºC until further analysis.</p>
                  </sec>
                  <sec>
                    <title>Plasma and Hemocyte Preparation</title>
                    <p>Plasma was prepared sequentially by centrifuging whole blood at 500 × <italic>g</italic> for 5 min and carefully collecting the upper layer (platelet-rich plasma). Additional centrifugation at 3,000 × <italic>g</italic> for 30 min yielded platelet-poor plasma that could be spun at 16,000 × <italic>g</italic> for 30 min to collect microparticle-free plasma (MFP). Washed hemocytes were generated by centrifuging whole blood at 500 × <italic>g</italic> for 5 min and replacing the plasma volume with HBSS+, followed by two more cycles of centrifugation and supernatant replacement with HBSS+. All centrifugations were performed at ambient temperature (24 °C).</p>
                  </sec>
                  <sec>
                    <title>Neutrophil and Erythrocyte Isolation</title>
                    <p>Neutrophils were isolated as described previously (<xref ref-type="bibr" rid="B37">37</xref>). Briefly, whole blood was layered onto Hypaque-Ficoll and centrifuged at 1100 × <italic>g</italic> for 30 min at room temperature (brake off), and the peripheral blood mononuclear cell/cord blood mononuclear cell layer and liquid phase were carefully removed. The upper portion of the RBC/granulocyte layer was carefully collected and resuspended in PBS before 1:1 dilution with a 3% dextran (Pharmacosmos) solution (in saline) followed by repeated inversion (10 times) prior to allowing the cells to settle for 20 min at room temperature. The leukocyte-rich upper layer was added to new tubes for centrifugation at 500 × <italic>g</italic> for 10 min. Erythrocytes were lysed by resuspending the pellet in H<sub>2</sub>O for 25 s, followed by immediate tonicity restoration with 2× PBS. Cells were spun again at 500 × <italic>g</italic>, and the resulting pellet was resuspended in HBSS− and spun again at 500 × <italic>g</italic> for 10 min. The final pellet was resuspended in HBSS+, and cell density was determined by hemocytometer and adjusted as necessary with HBSS+ to a density of 4 × 10<sup>6</sup> cells/ml (viability, as measured by trypan blue exclusion during quantitation, was &gt;90% for each sample). Erythrocytes were collected from the remaining cell pellet following RBC/granulocyte layer removal from Hypaque-Ficoll separation and were washed three times with HBSS+ (with centrifugation at 500 × <italic>g</italic> for 5 min) before resuspension in an equal volume of HBSS+ (500 μl of RBC cell pellet + 500 μl of HBSS+). The purity of erythrocytes (RBCs) collected by this method was evaluated by the absence of leukocytes in Wright-stained smears. RBC density was also determined by hemocytometer.</p>
                  </sec>
                  <sec>
                    <title>Enzyme Assays and Thin Layer Chromatography</title>
                    <p>Enzymatic modification of nucleotide and nucleoside substrates was evaluated utilizing [<sup>14</sup>C]ADP (PerkinElmer Life Sciences), [<sup>14</sup>C]AMP, and [<sup>14</sup>C]adenosine (Moravek Biochemicals). Substrates were added to prewarmed samples at a concentration of 0.5, 5.0, 50, or 200 μ<sc>m</sc>, as indicated, during gentle vortexing before incubating at 37 °C in a dry bath for specified times. The 50 μ<sc>m</sc> substrate concentration was selected for the majority of the samples to model putative responses during inflammatory tissue damage, during which elevated levels of extracellular purine substrate may be present, and also for technical considerations to aid in the detection of metabolic products. Plasma enzyme activity measurements utilizing a saturating concentration of substrate (200 μ<sc>m</sc>) and collection at multiple time points (times indicated) were used to calculate rates of activity in plasma and were within the linear range of activity. Samples with non-saturating levels of substrate are displayed as accumulated reaction product at the indicated time point. Reactions were terminated by adding 3 volumes of a solution containing 50 m<sc>m</sc> EDTA (Invitrogen) and 30 μ<sc>m</sc> EHNA (ADA inhibitor; Tocris) in HBSS (Invitrogen). Controls for analytes of interest ([<sup>14</sup>C]adenosine or [<sup>14</sup>C]inosine; Moravek) were prepared at assay-appropriate concentration ranges, and controls and samples were then applied to silica gel matrix thin layer chromatography plates (Sigma-Aldrich) and migrated until the solvent (6:3:1, 2-propanol/ammonium hydroxide/distilled H<sub>2</sub>O) front reached 4 cm beyond the application site. Plates were dried and incubated in a storage phosphor screen cassette overnight, after which the screens were analyzed on a GE Storm 860 Imager. Analytes were quantified relative to controls by densitometry utilizing ImageJ software (version 1.43u; National Institutes of Health). For assays utilizing 0.5 μ<sc>m</sc> [<sup>14</sup>C]adenosine substrate, plates were incubated in a storage phosphor screen cassette for 14 days before analysis.</p>
                  </sec>
                  <sec>
                    <title>Flow Cytometry</title>
                    <p>Whole blood was washed (2 ml of blood + 10 ml of HBSS+; centrifuged at 300 × <italic>g</italic> for 5 min; 10 ml supernatant removed and the remainder reconstituted) to remove the majority of plasma. Fluorochrome-conjugated monoclonal antibodies against CD3 (phycoerythrin-Cy7), CD19 (APC-Cy7), CD14 (Alexa Fluor 700), CD66b (PerCP Cy5.5), TNAP (phycoerythrin), and CD73/5′-NT (APC) (all from BD Biosciences); CD39/ENTPD1 (FITC; eBioscience); and ADA1 (Calbiochem; labeled in-house with Pacific Blue APEX antibody labeling kit per manufacturer's recommendations (Invitrogen), which was also performed for an isotype control antibody) or appropriate phycoerythrin-, APC-, and FITC-conjugated isotype control antibodies (BD Biosciences and eBiosciences) were added directly to 200 μl of washed whole blood at room temperature for 30 min. Samples were added to BD Facs lysing solution for 10 min and centrifuged at 500 × <italic>g</italic> for 5 min. Supernatants were removed, and cell pellets were washed with PBS and centrifuged again. Cell pellets were finally resuspended in 1% paraformaldehyde (VWR) and analyzed on a BD LSR II flow cytometer within 48 h. Data were collected uncompensated, and compensation, doublet exclusion, and data analysis were performed with FlowJo software (version 9.2; TreeStar).</p>
                  </sec>
                  <sec>
                    <title>ADA Chromogenic Assay</title>
                    <p>ADA1 and ADA2 activities in plasma samples were determined with an adenosine deaminase assay kit per the manufacturer's instructions (Diazyme Laboratories, Poway, CA), run in duplicate with or without EHNA (20 μ<sc>m</sc>). ADA2 is not EHNA-sensitive; thus, activity in EHNA-containing wells was considered to reflect ADA2 activity. ADA1 activity was calculated by subtracting ADA2 activity from total ADA activity.</p>
                  </sec>
                  <sec>
                    <title>Alkaline Phosphatase Isoform Assay</title>
                    <p>Blood was collected as described previously, but without anti-coagulant, and left at ambient temperature until coagulation (up to 2 h). Serum samples were then sent to Mayo Medical Laboratories for evaluation of alkaline phosphatase isoform content by electrophoresis through alkaline-buffered agarose gels with or without wheat germ lectin for separation, essentially as described previously (<xref ref-type="bibr" rid="B38">38</xref>), followed by an enzymatic assay with a chromogenic substrate, 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium in aminomethyl propanol buffer, pH 10.0, utilizing the Sebia Hydragel 7 and 15 ISO-PAL systems (Sebia, Norcross, GA). Results were reported in units/liter for bone, liver type 1, and liver type 2 AP. Intestinal AP was detected in 1 adult sample (10 units/liter). No placental or germ cell AP was reported.</p>
                  </sec>
                  <sec>
                    <title>Whole Blood Stimulation with Staphylococcus epidermidis</title>
                    <p>Experiments assessing bacteria-induced cytokine production employed <italic>S. epidermidis</italic> 1457, a clinical strain from a patient with a central catheter infection that was previously isolated by Mack <italic>et al.</italic> (<xref ref-type="bibr" rid="B39">39</xref>). Anti-coagulated whole blood was incubated with APCP (an inhibitor of 5′-NT) or buffer control before stimulation with 10<sup>7</sup> live <italic>S. epidermidis</italic>/ml, lipopolysaccharide (LPS; 1 μg/ml), or vehicle control for 4 h during end-over-end rotation at 37 °C. Supernatants were collected following centrifugation and stored at −80 °C prior to measurement of TNF-α, IL-6, IL-1β, IL-23, and IL-10 by ELISA per the manufacturer's recommendations (BD Biosciences for TNF-α and IL-10; eBioscience for IL-6, IL-23, and IL-1β).</p>
                    <p>Plasma alkaline phosphatase activity was evaluated in diethanolamine buffer with 1 m<sc>m</sc> Mg<sup>2+</sup>, 20 μ<sc>m</sc> Zn<sup>2+</sup> and 2.7 m<sc>m</sc>
<italic>p</italic>-nitrophenyl phosphate (Sigma) at pH 9.8 or 7.4, as indicated, at room temperature. 195 μl of buffer was added to 5 μl of sample in a 96-well plate (Corning Inc.), and absorbance at 405 nm was evaluated at 5, 10, and 15 min after reaction initiation. <italic>p</italic>-Nitrophenyl phosphate dephosphorylation product nitrophenyl phosphate was compared with serially diluted nitrophenyl phosphate controls of known concentrations, and the rate of nitrophenyl phosphate generation was calculated for each interval (and averaged). AP activity was calculated as units/liter, which is μmol of nitrophenyl phosphate generated/min/liter of plasma (μmol/min/liter). Samples were run in duplicate.</p>
                  </sec>
                </sec>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>RESULTS</title>
              <sec>
                <title/>
                <sec>
                  <title/>
                  <sec>
                    <title>Blood ATPase and ADPase Activities Are Largely Cell-associated, whereas AMPase Activity Is Largely Plasma-based</title>
                    <p>Given the importance of Ado as an endogenous immunoregulatory molecule and the previously discovered difference in Ado concentration between newborn and adult blood plasma (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B32">32</xref>), we sought to determine if different levels of enzymatic activity in whole blood contribute to the Ado bias in newborn plasma. To this end, radiolabeled ADP ([<sup>14</sup>C]ADP) was added to whole blood, washed hemocytes, or MFP in the presence of 100 μ<sc>m</sc> dipyridamole (to prevent cellular uptake of Ado), and at indicated times, blood-derived supernatants were collected for separation by thin layer chromatography (TLC) as described under “Materials and Methods.” In agreement with previous work employing adult blood (<xref ref-type="bibr" rid="B40">40</xref>), these studies indicated that in both neonatal cord and adult peripheral blood, dephosphorylation of ADP to generate AMP was primarily accomplished by cell-associated enzymes, but dephosphorylation of AMP to generate Ado mostly occurred in the soluble phase of blood (<xref ref-type="fig" rid="F1">Fig. 1</xref><italic>A</italic>). We did not detect significant differences in total AMPase activity in the different preparations of plasma (platelet-rich plasma, platelet-poor plasma, or MFP) but utilized MFP to more completely demonstrate the soluble nature of the enzymatic activity (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M113.484212/DC1">supplemental Fig. 1</ext-link>). Also, all blood was processed within 2 h of phlebotomy, during which time there was not significant shedding of AP or 5′-NT into the soluble phase of the blood (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M113.484212/DC1">supplemental Fig. 1</ext-link>).</p>
                    <fig id="F1" position="float">
                      <label>FIGURE 1.</label>
                      <caption>
                        <p><bold>Cell-associated enzymes dominate newborn and adult blood ADPase activity, whereas soluble enzymes dominate blood AMPase and ADA activities and are differentially expressed in newborns and adults.</bold> Whole blood, hemocytes, or plasma (MFP) were incubated with 50 μ<sc>m</sc> [<sup>14</sup>C]ADP for 5 or 15 min (<italic>A</italic>). MFP was incubated with 50 μ<sc>m</sc> [<sup>14</sup>C]AMP and 20 μ<sc>m</sc> EHNA (<italic>B</italic>) or 50 μ<sc>m</sc> [<sup>14</sup>C]adenosine (<italic>C</italic>) for 15 min prior to measurement of conversion to other purine metabolites by TLC. Shown is one representative of five (<italic>A</italic>) or six (<italic>B</italic> and <italic>C</italic>) independent experiments.</p>
                      </caption>
                      <graphic xlink:href="zbc0421361170001"/>
                    </fig>
                  </sec>
                  <sec>
                    <title>Leukocyte Expression of Purine Ectoenzymes by Flow Cytometry</title>
                    <p>To determine which cell types in blood expressed the candidate purine-regulating enzymes of interest, we measured CD39 (ENTPD1), CD73 (5′-NT), TNAP, and ADA1 and cell type markers CD3, CD19, CD14, and CD66b by polychromatic flow cytometry as described under “Materials and Methods” (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M113.484212/DC1">supplemental Fig. 2</ext-link>). In comparison with adults, neonates demonstrated the following differences in subpopulations: (<italic>a</italic>) CD19+ B cells had lower CD73 expression, in agreement with previous work (<xref ref-type="bibr" rid="B41">41</xref>), and higher TNAP (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M113.484212/DC1">supplemental Fig. 2<italic>B</italic></ext-link>), and (<italic>b</italic>) CD66b+ granulocytes had similar levels of CD39 and no detectable CD73 but significantly more TNAP and less ADA1 (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M113.484212/DC1">supplemental Fig. 2<italic>C</italic></ext-link>). Similar levels of CD39 were detected on newborn and adult CD14+ monocytes, whereas CD73, TNAP, and ADA1 were not detected on these cells (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M113.484212/DC1">supplemental Fig. 2<italic>D</italic></ext-link>).</p>
                  </sec>
                  <sec>
                    <title>Robust Neonatal Cord Blood Ado Generation Reflects Greater Cell ATPase/ADPase Activity, Greater Plasma AMPase Activity, and Lower Soluble ADA</title>
                    <p>Newborn blood generated significantly more Ado from ADP than adult blood. ADPase activity in blood is primarily mediated by cellular ENTPD1, and our flow cytometry studies (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M113.484212/DC1">supplemental Fig. 2</ext-link>) suggested that these activity rates are higher in newborns, due to the well documented elevated leukocyte densities of newborns (<xref ref-type="bibr" rid="B42">42</xref>) rather than higher per cell activity. Of note, the robust generation of Ado in newborn blood was also in part due to higher AMPase activity in neonatal blood plasma. To selectively measure AMPase activity, [<sup>14</sup>C]AMP was added to whole blood, washed hemocytes, or MFP in the presence of dipyridamole and 20 μ<sc>m</sc> EHNA (to inhibit deamination of Ado), and the production of Ado was measured by TLC. Although hemocytes did have some AMPase activity, the importance of soluble enzymes for the metabolism of AMP in blood was confirmed (<xref ref-type="fig" rid="F1">Fig. 1</xref><italic>B</italic>). Similarly, although detectable metabolism of [<sup>14</sup>C]Ado to inosine occurred on hemocytes, substantially greater activity was observed in plasma (<xref ref-type="fig" rid="F1">Fig. 1</xref><italic>C</italic>; all conditions included dipyridamole). The ADA activity associated with cells and in the plasma was completely EHNA-sensitive, indicating that ADA1 was responsible and not ADA2 (data not shown). AMPase and ADA activity assays, conducted in the absence of dipyridamole, demonstrated that newborn plasma had significantly more AMPase activity on average (<xref ref-type="fig" rid="F2">Fig. 2</xref><italic>A</italic>), and also significantly less ADA activity (<xref ref-type="fig" rid="F2">Fig. 2</xref><italic>B</italic>), than adult plasma, both of which could contribute to greater Ado generation in newborn blood. Plasma AMP to adenosine conversion and adenosine deamination were also measured in larger sets of samples with a 50 μ<sc>m</sc> substrate concentration, which may be more relevant in the context of tissue damage <italic>in vivo</italic> (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M113.484212/DC1">supplemental Fig. 3</ext-link>) (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>). Additionally, plasma adenosine deamination was measured with 0.5 μ<sc>m</sc> substrate (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M113.484212/DC1">supplemental Fig. 4</ext-link>), closer to the basal plasma adenosine levels (<xref ref-type="bibr" rid="B32">32</xref>). Preparations of plasma that included microparticles (platelet-poor plasma) and platelets (platelet-rich plasma) did not have AMPase activity (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M113.484212/DC1">supplemental Fig. 1<italic>A</italic></ext-link>) or ADA activity<xref ref-type="fn" rid="FN8"><sup>7</sup></xref> distinguishably different from that of MFP, which was used to evaluate the activity of soluble enzymes that were not associated with particles or platelets. Plasma microparticles do incorporate ENTPD1 (CD39), the activity of which influences endothelial cell activation (<xref ref-type="bibr" rid="B43">43</xref>).</p>
                    <fig id="F2" position="float">
                      <label>FIGURE 2.</label>
                      <caption>
                        <p><bold>Neonatal cord blood plasma demonstrates high AMPase and lower relative ADA activities.</bold><italic>A</italic>, soluble plasma (MFP) AMPase activity was determined by adding 200 μ<sc>m</sc> [<sup>14</sup>C]AMP for 5, 10, and 15 min in the presence of EHNA before reaction termination, and subsequent TLC was quantified by densitometry with the rate calculated based on the change in product between 5 and 10 min and between 10 and 15 min (which were equivalent and were averaged; <italic>n</italic> = 16 each population; Student's <italic>t</italic> test; *, <italic>p</italic> &lt; 0.05). <italic>B</italic>, soluble plasma (MFP) ADA activity was determined by adding 200 μ<sc>m</sc> [<sup>14</sup>C]adenosine for 30 and 60 min prior to reaction termination and TLC separation (<italic>n</italic> = 12 each population; Student's <italic>t</italic> test; *, <italic>p</italic> &lt; 0.05, rate calculated based on the change in product between 30 and 60 min). <italic>Error bars</italic>, S.E.</p>
                      </caption>
                      <graphic xlink:href="zbc0421361170002"/>
                    </fig>
                  </sec>
                  <sec>
                    <title>Soluble AP and CD73 Comprise the Majority of Blood AMPase Activity</title>
                    <p>To assess the relative contribution of soluble and cell-associated enzymes to blood AMPase activity, [<sup>14</sup>C]AMP (50 μ<sc>m</sc>) was added to either cell (<italic>i.e.</italic> hemocyte) or plasma blood fractions, with or without the addition of inhibitors of 5′-NT (APCP 100 μ<sc>m</sc>) or TNAP (MLS-0038949 (<xref ref-type="bibr" rid="B44">44</xref>) 100 μ<sc>m</sc>), and conversion to Ado was assessed. Of note, in both newborn and adult blood studied <italic>ex vivo</italic>, only a minority of blood AMPase activity was cell-associated. Upon incubation with 100 μ<sc>m</sc> MLS-0038949, 100 μ<sc>m</sc> APCP, or both and 50 μ<sc>m</sc> [<sup>14</sup>C]AMP, newborn hemocytes demonstrated a significantly higher conversion of AMP to adenosine than adult hemocytes (<xref ref-type="fig" rid="F3">Fig. 3</xref>). Experiments were performed at volumetric equivalence (<italic>i.e.</italic> not at equivalent cell numbers), and differences in cell density, known to be higher in newborn blood (<xref ref-type="bibr" rid="B42">42</xref>), probably contribute to observed differences in purine metabolism. Surprisingly, AP was responsible for a slight majority of newborn hemocyte-associated AMPase activity, with 5′-NT responsible for the remainder (<xref ref-type="fig" rid="F3">Fig. 3</xref>, <italic>A</italic> and <italic>C</italic>). In contrast, adult hemocytes demonstrated a reverse pattern, with 5′-NT responsible for a slight majority of total activity. In neutrophils isolated from peripheral venous blood, AMP conversion to adenosine was largely due to AP activity, with modest 5′-NT activity (<xref ref-type="fig" rid="F3">Fig. 3</xref>, <italic>B</italic> and <italic>D</italic>). Neutrophil AP-mediated ecto-AMPase activity was significantly higher on newborn cells than on adult cells. RBCs had very low levels of AMPase activity (data not shown) but represent the considerable majority of hemocyte ecto-ADA activity. Newborn and adult RBC ecto-ADA1 activity rates per cell, as assessed by measuring conversion of [<sup>14</sup>C]Ado to inosine as described under “Materials and Methods,” were not significantly different (data not shown).</p>
                    <fig id="F3" position="float">
                      <label>FIGURE 3.</label>
                      <caption>
                        <p><bold>Newborn neutrophils express relatively high AMPase activity.</bold> Newborn washed hemocytes (<italic>A</italic> and <italic>C</italic>) or isolated peripheral blood neutrophils (4 × 10<sup>6</sup>/ml) (<italic>B</italic> and <italic>D</italic>) were incubated with or without inhibitors of TNAP (MLS0038949; 100 μ<sc>m</sc>) and 5′-NT (APCP; 100 μ<sc>m</sc>) before the addition of 50 μ<sc>m</sc> [<sup>14</sup>C]AMP for 15 min in the presence of EHNA before reaction termination, and subsequent TLC separation was quantified by densitometry. <italic>A</italic>, <italic>n</italic> = 6 for both newborn and adult; <italic>B</italic>, <italic>n</italic> = 5 for newborn and <italic>n</italic> = 6 for adult. <italic>C</italic>, one representative of six independent experiments; <italic>D</italic>, one representative of five independent experiments. <italic>A</italic>, newborn <italic>versus</italic> adult control condition; Student's <italic>t</italic> test; ***, <italic>p</italic> = &lt;0.001; all other conditions compared with appropriate population (newborn or adult) control by analysis of variance with Bonferroni's multiple comparison test (♢) with <italic>p</italic> &lt; 0.01. <italic>B</italic>, newborn <italic>versus</italic> adult Student's <italic>t</italic> test; *, <italic>p</italic> &lt; 0.05; **, <italic>p</italic> &lt; 0.01; ***, <italic>p</italic> &lt; 0.001, all other conditions compared with population control by analysis of variance with Bonferroni's multiple comparison test, with <italic>p</italic> &lt; 0.01 unless indicated as not significant (<italic>ns</italic>). <italic>Error bars</italic>, S.E.</p>
                      </caption>
                      <graphic xlink:href="zbc0421361170003"/>
                    </fig>
                  </sec>
                  <sec>
                    <title>The Majority of Blood AMPase Activity Is Soluble</title>
                    <p>To determine which enzymes were responsible for the AMPase activity in plasma, the conversion of [<sup>14</sup>C]AMP (added at 50 μ<sc>m</sc>) to Ado in plasma (MFP) was assessed with or without the addition of inhibitors of 5′-NT (APCP; 100 μ<sc>m</sc>) or TNAP (MLS-0038949 (<xref ref-type="bibr" rid="B44">44</xref>); 100 μ<sc>m</sc>) as described under “Materials and Methods.” Although 5′-NT was primarily responsible for soluble AMPase activity, TNAP also significantly contributed (<xref ref-type="fig" rid="F4">Fig. 4</xref><italic>A</italic>). Because previous work (<xref ref-type="bibr" rid="B40">40</xref>) utilizing 1 μ<sc>m</sc> AMP substrate had ruled out a role for AP in plasma AMPase activity, we evaluated whether AP contributed to AMPase activity only at higher substrate concentrations. Although at a 5 μ<sc>m</sc> AMP concentration (<italic>i.e.</italic> basal AMP levels), AP did not substantially contribute (<xref ref-type="fig" rid="F4">Fig. 4</xref><italic>B</italic>), at a 100 μ<sc>m</sc> (<italic>i.e.</italic> pathophysiologic) AMP concentration, AP significantly contributed to plasma AMPase activity (<xref ref-type="fig" rid="F4">Fig. 4</xref><italic>C</italic>). In fact, the plasma AMPase rate, calculated with a substrate concentration of 200 μ<sc>m</sc>, demonstrates a significant positive relationship with plasma alkaline phosphatase activity (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M113.484212/DC1">supplemental Fig. 5</ext-link>). These observations suggest that plasma AP, known to be higher at birth (<xref ref-type="bibr" rid="B45">45</xref>), may play a substantial role in blood Ado generation when extracellular levels of purine nucleotides are substantially elevated during tissue damage or in a hypoxic environment. Thus, soluble AP appears to be critically involved in blood Ado production at elevated levels of extracellular purine precursors and to a greater extent in newborn than in adult blood; reduction in AMPase activity with TNAP inhibitor (MLS-0038949) for newborn plasma was 0.70 ± 0.56 μmol/liter/min compared with 0.31 ± 0.13 μmol/liter/min (<italic>p</italic> &lt; 0.05; Student's <italic>t</italic> test; <italic>n</italic> = 11 each population; shown as mean ± S.D., calculated from the <xref ref-type="fig" rid="F4">Fig. 4</xref><italic>A</italic> data set). We characterized the expression of AP isoforms at birth and found that neonatal plasma contains greater levels of TNAP (as expected (<xref ref-type="bibr" rid="B46">46</xref>)) and a distinct TNAP isoform profile compared with adult plasma (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M113.484212/DC1">supplemental Fig. 6</ext-link>). The majority of total AP at birth was the bone isoform of TNAP, although relative to adult plasma, neonatal plasma also contained high concentrations of the liver type 2 isoform of TNAP and lower liver TNAP isoform 1. We also confirmed that higher alkaline phosphatase activity in neonatal as compared with adult plasma was also noted when assayed at pH 7.4, further indicating the physiologic relevance of these findings.<sup>7</sup></p>
                    <fig id="F4" position="float">
                      <label>FIGURE 4.</label>
                      <caption>
                        <p><bold>TNAP and 5′-NT are key contributors to soluble plasma AMPase activity.</bold> The contributions of TNAP and 5′-NT were determined by the addition of a 100 μ<sc>m</sc> concentration of the selective inhibitor MLS0038949 or APCP, respectively. 50 μ<sc>m</sc> [<sup>14</sup>C]AMP was added in the presence of EHNA, and after 5 min, the reaction was terminated prior to TLC separation and quantified by densitometry (<italic>A</italic>; <italic>n</italic> = 11). TNAP did not influence total AMPase activity in plasma at low concentrations of substrate (<italic>B</italic>; 5 μ<sc>m</sc> [<sup>14</sup>C]AMP, 1 min, <italic>n</italic> = 8) but did significantly contribute at high concentrations (<italic>C</italic>; 100 μ<sc>m</sc> [<sup>14</sup>C]AMP; 5 min; <italic>n</italic> = 8; Student's <italic>t</italic> tests; *, <italic>p</italic> &lt; 0.05; **, <italic>p</italic> &lt; 0.01; ***, <italic>p</italic> &lt; 0.001). <italic>Error bars</italic>, S.E.</p>
                      </caption>
                      <graphic xlink:href="zbc0421361170004"/>
                    </fig>
                  </sec>
                  <sec>
                    <title>Age-dependent Increase in ADA during Infancy</title>
                    <p>We next characterized the ontogeny of soluble ADA1 and 5′-NT in two cohorts of infant plasma samples: (<italic>a</italic>) plasma collected in a cross-sectional study at birth and at 1, 2, 3, 4, 6, 9, and 12 months and (<italic>b</italic>) plasma collected in a separate longitudinal study at birth and at 1 and 2 years of age. ADA activity was assayed as described previously with [<sup>14</sup>C]Ado substrate. Of note, the plasma adenosine deamination was significantly higher at 1 and 2 years of age than at birth (<xref ref-type="fig" rid="F5">Fig. 5</xref><italic>A</italic>). In the cross-sectional study of West African (Gambian) infants, plasma adenosine deamination was significantly increased by 3 months of age as compared with birth (cord; <xref ref-type="fig" rid="F5">Fig. 5</xref><italic>B</italic>). A chromogenic ADA assay utilizing high concentrations of Ado substrate revealed that total ADA and ADA1 activities were significantly lower in newborn plasma, in agreement with our assay at more physiological concentrations of substrate (<xref ref-type="fig" rid="F5">Fig. 5</xref>, <italic>C–E</italic>). Activity in neonatal plasma of ADA2, a protein with weak deaminase activity (<xref ref-type="bibr" rid="B47">47</xref>) that probably functions rather as a growth factor (<xref ref-type="bibr" rid="B48">48</xref>), was not significantly different between newborn and adult plasma. No significant changes were observed in soluble 5′-NT activity in plasma during the first 2 years of life in the above described infant cohorts (data not shown).</p>
                    <fig id="F5" position="float">
                      <label>FIGURE 5.</label>
                      <caption>
                        <p><bold>Soluble plasma ADA levels increase significantly during the first year of life.</bold><italic>A</italic>, soluble ADA activity was determined by the addition of 50 μ<sc>m</sc> [<sup>14</sup>C]adenosine for 5 min to microparticle-free plasma collected at 0, 1, and 2 years of age from 12 subjects (paired Student's <italic>t</italic> tests; 0 <italic>versus</italic> 1, <italic>p</italic> &lt; 0.001; 0 <italic>versus</italic> 2, <italic>p</italic> &lt; 0.0001; 1 <italic>versus</italic> 2, <italic>p</italic> &lt; 0.01). <italic>B</italic>, a cohort of platelet-rich plasma samples from a previous study, including samples from cord blood and 1, 2, 3, 4, 6, 9, and 12 months of age (1 sample/subject), were processed to MFP and incubated with 50 μ<sc>m</sc> [<sup>14</sup>C]adenosine for 15 min (analysis of variance with Bonferroni's multiple comparison test; 0 <italic>versus</italic> 3 months, <italic>p</italic> &lt; 0.01; 0 <italic>versus</italic> 4 months, <italic>p</italic> &lt; 0.05). Total ADA (<italic>C</italic>), ADA1 (<italic>D</italic>), and ADA2 (<italic>E</italic>) activity were evaluated by a chromogenic assay as described under “Materials and Methods.” Total ADA (<italic>n</italic> = 11 newborn, <italic>n</italic> = 14 adult; Student's <italic>t</italic> test; **, <italic>p</italic> &lt; 0.01) (<italic>C</italic>) and ADA1 activity (<italic>n</italic> = 11 newborn; <italic>n</italic> = 14 adult; Student's <italic>t</italic> test; *, <italic>p</italic> &lt; 0.05) (<italic>D</italic>) were significantly lower in newborn samples. <italic>Error bars</italic>, S.E.</p>
                      </caption>
                      <graphic xlink:href="zbc0421361170005"/>
                    </fig>
                  </sec>
                  <sec>
                    <title>Inhibition of Blood 5′-NT Activity Enhances whereas the Addition of AMP Inhibits TLR-mediated TNF-α Production in Blood</title>
                    <p>To assess the potential functional relevance of robust Ado-generating activity in human newborn cord blood, we tested the effect of selective inhibition of 5′-NT. To this end, human newborn cord and adult peripheral blood were incubated with vehicle control or with the 5′-NT-selective inhibitor APCP. Because our prior studies suggested that Ado may particularly affect polarization of TLR2-mediated cytokine production (<xref ref-type="bibr" rid="B32">32</xref>), we assessed the impact of 5′-NT inhibition on cytokine induction by <italic>S. epidermidis</italic>, a Gram-positive pathogen that causes neonatal bacteremia and signals via TLR2 (<xref ref-type="bibr" rid="B49">49</xref>). Consistent with a role for Ado in inhibiting neonatal TNF-α induction, the addition of APCP significantly and selectively enhanced <italic>S. epidermidis</italic>-induced production of the proinflammatory/Th1-polarizing cytokine TNF-α in newborn whole blood (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M113.484212/DC1">supplemental Fig. 7</ext-link>). In contrast, <italic>S. epidermidis</italic>-induced production of IL-1β and of the Th17-polarizing cytokines IL-6 and IL-23 and of the anti-inflammatory cytokine IL-10 was not affected by the addition of APCP, indicating cytokine-specific Ado effects on neonatal leukocytes. It should be noted that <italic>S. epidermidis</italic> expresses a 5′-NT homologue (<xref ref-type="bibr" rid="B50">50</xref>), AdsA, which is also inhibited by APCP and would have contributed to AMPase activity in this assay. A modest enhancement of newborn TNF-α in response to LPS (TLR4) in the presence of APCP did not reach significance, and the other cytokines tested were unaffected (data not shown). TNF-α in control whole blood samples was low but detectable and was not significantly different between newborn and adult samples (data not shown).</p>
                    <p>Additionally, we have evaluated the ability of AMP or Ado to modulate the production of proinflammatory cytokine (TNF-α) in a 96-well plate format whole blood assay. Newborn cord or adult peripheral blood was diluted with RPMI and treated with LPS (TLR4 agonist; 100 ng/ml) or mock-treated with RPMI in the presence or absence of 100 μ<sc>m</sc> AMP or Ado. Additional wells were treated again with 100 μ<sc>m</sc> AMP or Ado 2 h after the initial stimulation (other wells received an addition of RPMI at this time point, and all wells were mixed gently). After a total of 4 h of incubation, cells were pelleted by centrifugation at 500 × <italic>g</italic> for 5 min, and supernatants were evaluated by ELISA for TNF-α (<xref ref-type="fig" rid="F6">Fig. 6</xref>). Because no receptor has been described for AMP, the effect of AMP is presumed to be mediated by Ado following dephosphorylation of AMP. AMP and Ado addition diminished TNF-α production. In samples treated twice, AMP and Ado were significantly more inhibitory in newborn cord than in adult peripheral blood. The increased sensitivity in the newborn population to AMP may be due to elevated AMPase activity or greater sensitivity to the metabolic product Ado, whereas increased sensitivity to Ado may also be related to a deficiency in the newborn samples of ADA, resulting in slower clearance of Ado. We evaluated the plasma AMPase activity from the same blood samples used in <xref ref-type="fig" rid="F6">Fig. 6</xref><italic>A</italic> to determine if there was a correlation between plasma AMPase activity and TNF-α production. There was a significant, negative relationship between plasma AMPase activity and whole blood TNF-α production; samples with higher AMPase activity produced less TNF-α in response to LPS (<xref ref-type="fig" rid="F6">Fig. 6</xref><italic>B</italic>).</p>
                    <fig id="F6" position="float">
                      <label>FIGURE 6.</label>
                      <caption>
                        <p>Extracellular AMP metabolism leads to diminished LPS-induced TNF-α production in newborn and adult blood (<italic>A</italic>). Newborn cord or adult peripheral blood was diluted 1:1 (final) with RPMI and treated with LPS (100 ng/ml) or mock-treated with RPMI and treated with 100 μ<sc>m</sc> AMP or Ado once (at start) or twice (second addition at 2 h), as indicated, and all wells were mixed gently at the 2 h time point. After a total of 4 h of incubation (37 °C, 5% CO<sub>2</sub>, 96-well round bottom plates), supernatants were evaluated by ELISA for TNF-α (<italic>n</italic> = 13 newborn, <italic>n</italic> = 15 adult; Student's <italic>t</italic> test; *, <italic>p</italic> &lt; 0.05). Whole blood samples with higher plasma AMPase activity produce less TNF-α in response to LPS (<italic>B</italic>). Plasma AMP dephosphorylation to adenosine was determined as in <xref ref-type="fig" rid="F3">Fig. 3</xref>; <italic>n</italic> = 11 for each population; statistical analysis by linear regression, significantly non-zero slope for adult and combined populations; *, <italic>p</italic> &lt; 0.05; newborn population not significant. <italic>Error bars</italic>, S.E.</p>
                      </caption>
                      <graphic xlink:href="zbc0421361170006"/>
                    </fig>
                  </sec>
                </sec>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>DISCUSSION</title>
              <p>Our study has characterized Ado-generating and metabolizing activity in human neonatal blood. eATP and eAdo signaling impacts and regulates a wide variety of cellular functions, and thus the regulation of these molecules in the extracellular space is critical. Because eAdo is elevated in newborn blood, which potentially influences differential immunological function in this population (<xref ref-type="bibr" rid="B28">28</xref>), we assessed whether newborn eAdo regulation in blood differed from that in adults and identified the enzymes involved. We found that ATPase and ADPase activity in whole blood is primarily mediated by cell-associated ENTPD1 (CD39) (<xref ref-type="bibr" rid="B51">51</xref>), and although such hemocyte activity was higher by volume in newborn blood (<xref ref-type="fig" rid="F1">Fig. 1</xref><italic>A</italic>), this may reflect greater numbers of leukocytes at birth (<xref ref-type="bibr" rid="B52">52</xref>). Thus, eATP and extracellular ADP dephosphorylation appears to be higher in newborn blood due to elevated numbers of leukocytes, which express similar levels of ENTPD1 per cell compared with adult cells. AP significantly contributes to cell-associated AMPase activity and, at elevated levels of AMP (≥50 μ<sc>m</sc>), comprises the majority of cellular AMPase activity in blood at birth (<xref ref-type="fig" rid="F4">Fig. 4</xref>, <italic>B</italic> and <italic>C</italic>). Although we found modest levels of AP expression on subsets of circulating lymphocytes by flow cytometry (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M113.484212/DC1">supplemental Fig. 1<italic>A</italic></ext-link>), CD66b + granulocytes (primarily neutrophils) express abundant AP but low CD73 at birth (for expression, see <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M113.484212/DC1">supplemental Fig. 1<italic>C</italic></ext-link>; for activity, see <xref ref-type="fig" rid="F3">Fig. 3</xref><italic>B</italic>). Because purinergic signaling and ectopurine metabolism are critical for several aspects of neutrophil function (<xref ref-type="bibr" rid="B9">9</xref>), including chemotaxis (<xref ref-type="bibr" rid="B53">53</xref>), future work will focus on the functional implications of greater granulocyte-associated AP expression at birth.</p>
              <p>In marked contrast to the dephosphorylation of ATP and ADP in blood that is largely cell-based, extracellular dephosphorylation of AMP in newborn cord and adult peripheral blood is primarily accomplished by soluble plasma factors, specifically soluble 5′-NT and APs (see model in <xref ref-type="fig" rid="F7">Fig. 7</xref>). Of note, 5′-NT is also expressed on endothelial cells (<xref ref-type="bibr" rid="B11">11</xref>), and <italic>in vivo</italic>, this may significantly impact blood AMPase activity.</p>
              <fig id="F7" position="float">
                <label>FIGURE 7.</label>
                <caption>
                  <p><bold>Distinct purine metabolism at birth results in higher ambient adenosine concentrations.</bold> This figure presents a model that synthesizes both published and novel information from this current study highlighting age-specific differences in sequential cell- and plasma-based generation of Ado from ATP and of deamination of Ado to inosine (<italic>Ino</italic>). <italic>A</italic>, newborn blood contains a high density of CD39/ENTPD1-expressing leukocytes, contributing to high ATPase and ADPase activity (<italic>i</italic>); high plasma concentration of 5′-NT and AP that drive conversion of AMP to Ado (<italic>ii</italic>); and relative deficiency of ADA, resulting in a net increase in ambient adenosine concentrations and capacity to generate adenosine following release of purine substrates (<italic>iii</italic>). <italic>B</italic>, in marked contrast, adult blood features lower density of CD39/ENTPD1-expressing leukocytes (<italic>i</italic>), lower plasma 5′-NT and AP activity (<italic>ii</italic>), and relatively greater ADA activity, resulting in lower basal adenosine concentrations (<italic>iii</italic>).</p>
                </caption>
                <graphic xlink:href="zbc0421361170007"/>
              </fig>
              <p>There are four human AP genes: <italic>ALPL</italic> (tissue-nonspecific AP, high levels in bone, kidney, and liver but widely expressed in other tissues as well), <italic>ALPP</italic> (placental AP), <italic>ALPPL2</italic> (germ cell AP), and <italic>ALPI</italic> (intestinal AP) (<xref ref-type="bibr" rid="B45">45</xref>). We found that the majority of total AP at birth was the bone isoform of the <italic>ALPL</italic> gene product (TNAP), although relative to adult plasma, neonatal plasma also contained relatively high concentrations of liver type 2 isoform TNAP and lower liver TNAP isoform 1 (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M113.484212/DC1">supplemental Fig. 6</ext-link>). Serum AP levels, predominantly the bone isoform of TNAP early in life, are elevated during infancy and childhood compared with adulthood (<xref ref-type="bibr" rid="B54">54</xref>). In agreement with our results (<xref ref-type="fig" rid="F3">Fig. 3</xref><italic>B</italic>), TNAP did not measurably contribute to AMP hydrolysis in blood at 1 μ<sc>m</sc> AMP substrate (<xref ref-type="bibr" rid="B40">40</xref>). However, at elevated levels of the purine substrate AMP (&gt;50 μ<sc>m</sc>), AP significantly contributed to purine metabolism (<xref ref-type="fig" rid="F3">Fig. 3</xref><italic>C</italic> and <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M113.484212/DC1">supplemental Fig. 5</ext-link>). There appears to be a wide range of (patho)physiologically relevant purine concentrations <italic>in vivo</italic>. Low concentrations of eATP (0.01–0.1 μ<sc>m</sc>) are released from resting cells, and transient moderate increases in eATP (to &lt;5 μ<sc>m</sc>) mediate critical cell signaling functions (<xref ref-type="bibr" rid="B17">17</xref>). Larger releases of eATP (<italic>e.g.</italic> in the context of cellular damage) constitute a danger signal, reaching ∼10–20 μ<sc>m</sc> in rat and human blood following vascular injury (<xref ref-type="bibr" rid="B55">55</xref>) and &gt;100 μ<sc>m</sc> in murine tumor interstitia (<xref ref-type="bibr" rid="B56">56</xref>). <italic>In vitro</italic> EC<sub>50</sub> values for the P2X and P2Y eATP receptors have been estimated to be as low as 0.05 μ<sc>m</sc> for P2X<sub>1</sub> and as high as 780 μ<sc>m</sc> for P2X<sub>7</sub> (<xref ref-type="bibr" rid="B9">9</xref>), which plays a critical role in inflammatory responses to intracellular pathogens (<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B58">58</xref>). eAdo is generated primarily via metabolism of eAMP from extracellular ADP and eATP released from platelets and cells (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B17">17</xref>). EC<sub>50</sub> values for the adenosine receptors have been estimated to be as low as 0.18 μ<sc>m</sc> (A<sub>1</sub>) and as high as 64.1 μ<sc>m</sc> (A<sub>2B</sub>) (<xref ref-type="bibr" rid="B9">9</xref>). eAdo concentrations in the murine central nervous system are typically in the 0.01–0.1 μ<sc>m</sc> range but upon systemic insult increase into the &gt;1 μ<sc>m</sc> range (<xref ref-type="bibr" rid="B59">59</xref>), having been measured as high as 40 μ<sc>m</sc> (<xref ref-type="bibr" rid="B60">60</xref>). Working within the limits of detection of the thin layer chromatography assay, we have herein studied enzymatic regulation of extracellular purines in blood and blood plasma <italic>ex vivo</italic> utilizing substrate concentrations at 0.5 μ<sc>m</sc> eAdo, close to basal plasma eAdo concentrations (∼0.15 and 0.05 μ<sc>m</sc> eAdo in newborns and adults, respectively (<xref ref-type="bibr" rid="B32">32</xref>)). For the purposes of measuring enzymatic rates at elevated and saturating concentrations, we have also characterized these plasma enzymes at 50 and 200 μ<sc>m</sc> eAdo and eAMP, which are relatively high purine substrate concentrations that might be achieved locally during pathophysiologic states of injury and inflammatory tissue damage. Overall, our results indicate that neonatal purine-metabolizing enzymatic activity is significantly and consistently different from that of adults across a range of substrate concentrations, such that neonatal plasma will generate more eAdo and metabolize less of that eAdo to inosine, resulting in the higher ambient eAdo concentrations. Our results are probably valid in that (<italic>a</italic>) age-dependent maturation of ADA expression was observed across multiple and diverse newborn and infant cohorts in Boston, The Gambia (West Africa), and British Columbia, and (<italic>b</italic>) they are consistent with the higher newborn than adult plasma eAdo concentrations measured <italic>ex vivo</italic> (<xref ref-type="bibr" rid="B32">32</xref>).</p>
              <p>Overall, enzymatic generation of eAdo is higher in newborn blood than in adult blood, and enzymatic deamination of eAdo is lower, favoring elevated levels of eAdo in this population (see model in <xref ref-type="fig" rid="F7">Fig. 7</xref>). Of note, we also demonstrate that higher soluble AMPase activity correlates with lower LPS-induced proinflammatory TNF-α production in blood stimulated with LPS (<xref ref-type="fig" rid="F6">Fig. 6</xref><italic>B</italic>). Thus, the endogenous purine enzyme profile may critically regulate innate immune responses. Moreover, consistent with our prior studies (<xref ref-type="bibr" rid="B32">32</xref>), neonatal leukocytes appeared to be more sensitive to the inhibitory effects of Ado in that addition of AMP resulted in more profound inhibition of LPS-induced TNF production in newborn than in adult blood. Our demonstration that inhibition of 5′-NT activity with APCP enhances TNF production induced by <italic>S. epidermidis</italic>, a bacterium that activates human leukocyte cytokine production via TLR2 (<xref ref-type="bibr" rid="B49">49</xref>), also suggests that such eAdo generation may be functionally relevant, contributing to suppression of proinflammatory/Th1-polarizing cytokine while not influencing Th17-polarizing cytokines, such as IL-6, and anti-inflammatory cytokines, such as IL-10 (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M113.484212/DC1">supplemental Fig. 7</ext-link>). Such patterns of low Th1 but preserved Th2/Th17/anti-inflammatory fetal/neonatal cytokine production have been observed <italic>in vitro</italic> and <italic>in vivo</italic> (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B62">62</xref>). This cytokine skew may serve to limit fetal-maternal alloimmune reactions and excessive inflammation upon initial colonization in early life but may also render the newborn more susceptible to infections with intracellular pathogens and impair vaccine responses.</p>
              <p>The immunosuppressive activity of Ado is abrogated by ADA-mediated deamination of Ado to generate inosine. ADA1 (ADA) is primarily responsible for the deamination of Ado at physiological levels of substrate (<xref ref-type="bibr" rid="B19">19</xref>), whereas both ADA1 and ADA2 (<italic>CECR1</italic>) have co-stimulatory and growth factor activities. Extracellular ADA is found either soluble in fluids or cell-associated via binding to CD26 (<xref ref-type="bibr" rid="B26">26</xref>), or Ado receptors (<xref ref-type="bibr" rid="B27">27</xref>). ADA1 expression is not well characterized in newborns unless it is entirely absent, as in ADA deficiency causing severe combined immunodeficiency (<xref ref-type="bibr" rid="B63">63</xref>). We have discovered a physiologic deficiency of soluble plasma ADA at birth and characterized the age-dependent maturation of plasma ADA expression across two international cohorts, revealing that levels of this key enzyme gradually rise during the first year of life. Whereas the uncommon genetic deficiency of ADA severely impairs multiple immune responses in effected individuals, our discovery of a relative physiologic ADA deficiency that is apparently normal at birth and early infancy suggests a potential mechanism that may contribute to the general susceptibility of healthy newborns to bacterial, mycobacterial, and viral infections (<xref ref-type="bibr" rid="B64">64</xref>). Of note, a similar profile (elevated plasma AP (<xref ref-type="bibr" rid="B65">65</xref>), 5′-NT (<xref ref-type="bibr" rid="B66">66</xref>), and eAdo (<xref ref-type="bibr" rid="B66">66</xref>) and lower total ADA (but not lower ADA1) (<xref ref-type="bibr" rid="B67">67</xref>)) is found during pregnancy, another functionally distinct immunologic state associated with impaired Th1-polarizing cytokine responses and enhanced susceptibility to intracellular pathogens (<xref ref-type="bibr" rid="B68">68</xref>, <xref ref-type="bibr" rid="B69">69</xref>).</p>
              <p>Our results may also have translational implications. First, a great deal of preclinical biomedical research directed at development of immunomodulatory agents, such as immune response modifiers, adjuvants, and vaccines, employs <italic>in vitro</italic> assays of leukocytes. To the extent that eAdo exerts relevant immunomodulatory effects, such efforts to model age-specific immune responses <italic>in vitro</italic> should take into account that plasma demonstrates age-specific Ado-generating activity. Accordingly, rather than culturing the leukocytes to be compared in artificial media or heat-treated pooled adult sera, as is often done, such assays may be optimally conducted by employing age-specific plasma matched to the age of the individuals from which the leukocytes are isolated. From a therapeutic standpoint, multiple purine analogues, such as adenosine, caffeine, and imiquimod, are used clinically, and several others are in biopharmaceutical development. Imidazoquinolines, such as the FDA-approved topical antiviral agent imiquimod, are small synthetic purine analogues that activate TLR7 and/or TLR8, which also interact with the Ado system (<xref ref-type="bibr" rid="B70">70</xref>–<xref ref-type="bibr" rid="B72">72</xref>). Certain imidazoquinolines that are relatively more refractory to the inhibitory effects of Ado, such as the TLR7/8 agonist R-848 (resiquimod), are particularly effective in activating human neonatal monocytes and monocyte-derived dendritic cells, suggesting potential as neonatal immune response modifiers and/or vaccine adjuvants (<xref ref-type="bibr" rid="B73">73</xref>). To the extent that enhancement of neonatal immune responses may be beneficial, as has been demonstrated in neonatal murine studies (<xref ref-type="bibr" rid="B74">74</xref>), agents that are relatively refractory to Ado inhibition or that inhibit AP and/or 5′-NT (thereby reducing generation of Ado) may enhance neonatal host defense (<xref ref-type="bibr" rid="B75">75</xref>).</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="PMC_1" content-type="local-data">
                <caption>
                  <title>Supplemental Data</title>
                </caption>
                <media mimetype="text" mime-subtype="html" xlink:href="supp_288_38_27315__index.html"/>
                <media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_M113.484212_jbc.M113.484212-1.pdf"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="supported-by" id="FN1">
                <label>*</label>
                <p>This work was supported, in whole or in part, by National Institutes of Health (NIH) Grant 1R01AI100135-01 (to O. L.); NIH Training Grant T32 HD055148 (to M. P.); NIH Grants R01 HL094400, R21 CA164970, and P01 HL087203 (to S. R.); NIH, NIDCR, Grant R01 DE012889 and NIH, NIAMS, Grant R01 AR053102 (to J. L. M.); and NIH, NIAID, Grant N01 AI50023 (to T. R. K.).</p>
              </fn>
              <fn fn-type="supplementary-material" id="FN2">
                <label>
                  <inline-graphic xlink:href="sbox.jpg"/>
                </label>
                <p>This article contains <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M113.484212/DC1">supplemental Figs. 1–7</ext-link>.</p>
              </fn>
              <fn fn-type="other" id="FN8">
                <label>7</label>
                <p>M. Pettengill, S. Robson, M. Tresenriter, J. L. Millán, A. Usheva, T. Bingham, M. Belderbos, I. Bergelson, S. Burl, B. Kampmann, L. Gelinas, T. Kollmann, L. Bont, and O. Levy, unpublished observations.</p>
              </fn>
            </fn-group>
            <fn-group content-type="abbreviations">
              <fn id="FN7">
                <label>6</label>
                <p>The abbreviations used are:
<def-list><def-item><term id="G1">eATP</term><def><p>extracellular ATP</p></def></def-item><def-item><term id="G2">Ado</term><def><p>adenosine</p></def></def-item><def-item><term id="G3">eAdo</term><def><p>extracellular Ado</p></def></def-item><def-item><term id="G4">ENTPD</term><def><p>ectonucleoside triphosphate diphosphohydrolase</p></def></def-item><def-item><term id="G5">AP</term><def><p>alkaline phosphatase</p></def></def-item><def-item><term id="G6">5′-NT</term><def><p>ecto-5′-nucleotidase</p></def></def-item><def-item><term id="G7">TLR</term><def><p>Toll-like receptor</p></def></def-item><def-item><term id="G8">TNAP</term><def><p>tissue-nonspecific alkaline phosphatase</p></def></def-item><def-item><term id="G9">APCP</term><def><p>adenosine 5′-(α,β-methylene)-diphosphate</p></def></def-item><def-item><term id="G10">HBSS</term><def><p>Hanks' buffered salt solution</p></def></def-item><def-item><term id="G11">EHNA</term><def><p><italic>erythro</italic>-9-(2-hydroxy-3-nonyl)adenine hydrochloride</p></def></def-item><def-item><term id="G12">dipyridamole</term><def><p>2,6-bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-<italic>d</italic>]pyrimidine</p></def></def-item><def-item><term id="G13">MFP</term><def><p>microparticle-free plasma</p></def></def-item><def-item><term id="G14">RBC</term><def><p>red blood cell</p></def></def-item><def-item><term id="G15">ADA</term><def><p>adenosine deaminase</p></def></def-item><def-item><term id="G16">TLC</term><def><p>thin layer chromatography.</p></def></def-item></def-list></p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgments</title>
              <p>We thank Christy Mancuso for technical support as well as Dr. Michael Wessels for several helpful discussions regarding the manuscript.</p>
            </ack>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="B1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schenk</surname><given-names>U.</given-names></name><name><surname>Westendorf</surname><given-names>A. M.</given-names></name><name><surname>Radaelli</surname><given-names>E.</given-names></name><name><surname>Casati</surname><given-names>A.</given-names></name><name><surname>Ferro</surname><given-names>M.</given-names></name><name><surname>Fumagalli</surname><given-names>M.</given-names></name><name><surname>Verderio</surname><given-names>C.</given-names></name><name><surname>Buer</surname><given-names>J.</given-names></name><name><surname>Scanziani</surname><given-names>E.</given-names></name><name><surname>Grassi</surname><given-names>F.</given-names></name></person-group> (<year>2008</year>) <article-title>Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels</article-title>. <source>Sci. Signal</source>. <volume>1</volume>, <fpage>ra6</fpage><pub-id pub-id-type="pmid">18827222</pub-id></mixed-citation>
              </ref>
              <ref id="B2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filippini</surname><given-names>A.</given-names></name><name><surname>Taffs</surname><given-names>R. E.</given-names></name><name><surname>Sitkovsky</surname><given-names>M. V.</given-names></name></person-group> (<year>1990</year>) <article-title>Extracellular ATP in T-lymphocyte activation. Possible role in effector functions</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A</source>. <volume>87</volume>, <fpage>8267</fpage>–<lpage>8271</lpage><pub-id pub-id-type="pmid">2146684</pub-id></mixed-citation>
              </ref>
              <ref id="B3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baricordi</surname><given-names>O. R.</given-names></name><name><surname>Ferrari</surname><given-names>D.</given-names></name><name><surname>Melchiorri</surname><given-names>L.</given-names></name><name><surname>Chiozzi</surname><given-names>P.</given-names></name><name><surname>Hanau</surname><given-names>S.</given-names></name><name><surname>Chiari</surname><given-names>E.</given-names></name><name><surname>Rubini</surname><given-names>M.</given-names></name><name><surname>Di Virgilio</surname><given-names>F.</given-names></name></person-group> (<year>1996</year>) <article-title>An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes</article-title>. <source>Blood</source>
<volume>87</volume>, <fpage>682</fpage>–<lpage>690</lpage><pub-id pub-id-type="pmid">8555491</pub-id></mixed-citation>
              </ref>
              <ref id="B4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baricordi</surname><given-names>O. R.</given-names></name><name><surname>Melchiorri</surname><given-names>L.</given-names></name><name><surname>Adinolfi</surname><given-names>E.</given-names></name><name><surname>Falzoni</surname><given-names>S.</given-names></name><name><surname>Chiozzi</surname><given-names>P.</given-names></name><name><surname>Buell</surname><given-names>G.</given-names></name><name><surname>Di Virgilio</surname><given-names>F.</given-names></name></person-group> (<year>1999</year>) <article-title>Increased proliferation rate of lymphoid cells transfected with the P2X<sub>7</sub> ATP receptor</article-title>. <source>J. Biol. Chem</source>. <volume>274</volume>, <fpage>33206</fpage>–<lpage>33208</lpage><pub-id pub-id-type="pmid">10559192</pub-id></mixed-citation>
              </ref>
              <ref id="B5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sud'ina</surname><given-names>G. F.</given-names></name><name><surname>Mirzoeva</surname><given-names>O. K.</given-names></name><name><surname>Galkina</surname><given-names>S. I.</given-names></name><name><surname>Pushkareva</surname><given-names>M. A.</given-names></name><name><surname>Ullrich</surname><given-names>V.</given-names></name></person-group> (<year>1998</year>) <article-title>Involvement of ecto-ATPase and extracellular ATP in polymorphonuclear granulocyte-endothelial interactions</article-title>. <source>FEBS Lett</source>. <volume>423</volume>, <fpage>243</fpage>–<lpage>248</lpage><pub-id pub-id-type="pmid">9512366</pub-id></mixed-citation>
              </ref>
              <ref id="B6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cockcroft</surname><given-names>S.</given-names></name><name><surname>Stutchfield</surname><given-names>J.</given-names></name></person-group> (<year>1989</year>) <article-title>ATP stimulates secretion in human neutrophils and HL60 cells via a pertussis toxin-sensitive guanine nucleotide-binding protein coupled to phospholipase C</article-title>. <source>FEBS Lett</source>. <volume>245</volume>, <fpage>25</fpage>–<lpage>29</lpage><pub-id pub-id-type="pmid">2494077</pub-id></mixed-citation>
              </ref>
              <ref id="B7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balazovich</surname><given-names>K. J.</given-names></name><name><surname>Boxer</surname><given-names>L. A.</given-names></name></person-group> (<year>1990</year>) <article-title>Extracellular adenosine nucleotides stimulate protein kinase C activity and human neutrophil activation</article-title>. <source>J. Immunol</source>. <volume>144</volume>, <fpage>631</fpage>–<lpage>637</lpage><pub-id pub-id-type="pmid">2153172</pub-id></mixed-citation>
              </ref>
              <ref id="B8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Shukla</surname><given-names>A.</given-names></name><name><surname>Namiki</surname><given-names>S.</given-names></name><name><surname>Insel</surname><given-names>P. A.</given-names></name><name><surname>Junger</surname><given-names>W. G.</given-names></name></person-group> (<year>2004</year>) <article-title>A putative osmoreceptor system that controls neutrophil function through the release of ATP, its conversion to adenosine, and activation of A2 adenosine and P2 receptors</article-title>. <source>J. Leukoc. Biol</source>. <volume>76</volume>, <fpage>245</fpage>–<lpage>253</lpage><pub-id pub-id-type="pmid">15107462</pub-id></mixed-citation>
              </ref>
              <ref id="B9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bours</surname><given-names>M. J.</given-names></name><name><surname>Swennen</surname><given-names>E. L.</given-names></name><name><surname>Di Virgilio</surname><given-names>F.</given-names></name><name><surname>Cronstein</surname><given-names>B. N.</given-names></name><name><surname>Dagnelie</surname><given-names>P. C.</given-names></name></person-group> (<year>2006</year>) <article-title>Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation</article-title>. <source>Pharmacol. Ther</source>. <volume>112</volume>, <fpage>358</fpage>–<lpage>404</lpage><pub-id pub-id-type="pmid">16784779</pub-id></mixed-citation>
              </ref>
              <ref id="B10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cronstein</surname><given-names>B. N.</given-names></name><name><surname>Levin</surname><given-names>R. I.</given-names></name><name><surname>Belanoff</surname><given-names>J.</given-names></name><name><surname>Weissmann</surname><given-names>G.</given-names></name><name><surname>Hirschhorn</surname><given-names>R.</given-names></name></person-group> (<year>1986</year>) <article-title>Adenosine. An endogenous inhibitor of neutrophil-mediated injury to endothelial cells</article-title>. <source>J. Clin. Invest</source>. <volume>78</volume>, <fpage>760</fpage>–<lpage>770</lpage><pub-id pub-id-type="pmid">3745437</pub-id></mixed-citation>
              </ref>
              <ref id="B11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eltzschig</surname><given-names>H. K.</given-names></name><name><surname>Thompson</surname><given-names>L. F.</given-names></name><name><surname>Karhausen</surname><given-names>J.</given-names></name><name><surname>Cotta</surname><given-names>R. J.</given-names></name><name><surname>Ibla</surname><given-names>J. C.</given-names></name><name><surname>Robson</surname><given-names>S. C.</given-names></name><name><surname>Colgan</surname><given-names>S. P.</given-names></name></person-group> (<year>2004</year>) <article-title>Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation. Coordination by extracellular nucleotide metabolism</article-title>. <source>Blood</source>
<volume>104</volume>, <fpage>3986</fpage>–<lpage>3992</lpage><pub-id pub-id-type="pmid">15319286</pub-id></mixed-citation>
              </ref>
              <ref id="B12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouma</surname><given-names>M. G.</given-names></name><name><surname>Jeunhomme</surname><given-names>T. M.</given-names></name><name><surname>Boyle</surname><given-names>D. L.</given-names></name><name><surname>Dentener</surname><given-names>M. A.</given-names></name><name><surname>Voitenok</surname><given-names>N. N.</given-names></name><name><surname>van den Wildenberg</surname><given-names>F. A.</given-names></name><name><surname>Buurman</surname><given-names>W. A.</given-names></name></person-group> (<year>1997</year>) <article-title>Adenosine inhibits neutrophil degranulation in activated human whole blood. Involvement of adenosine A2 and A3 receptors</article-title>. <source>J. Immunol</source>. <volume>158</volume>, <fpage>5400</fpage>–<lpage>5408</lpage><pub-id pub-id-type="pmid">9164961</pub-id></mixed-citation>
              </ref>
              <ref id="B13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cronstein</surname><given-names>B. N.</given-names></name><name><surname>Kramer</surname><given-names>S. B.</given-names></name><name><surname>Weissmann</surname><given-names>G.</given-names></name><name><surname>Hirschhorn</surname><given-names>R.</given-names></name></person-group> (<year>1983</year>) <article-title>Adenosine. A physiological modulator of superoxide anion generation by human neutrophils</article-title>. <source>J. Exp. Med</source>. <volume>158</volume>, <fpage>1160</fpage>–<lpage>1177</lpage><pub-id pub-id-type="pmid">6311934</pub-id></mixed-citation>
              </ref>
              <ref id="B14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cronstein</surname><given-names>B. N.</given-names></name><name><surname>Rosenstein</surname><given-names>E. D.</given-names></name><name><surname>Kramer</surname><given-names>S. B.</given-names></name><name><surname>Weissmann</surname><given-names>G.</given-names></name><name><surname>Hirschhorn</surname><given-names>R.</given-names></name></person-group> (<year>1985</year>) <article-title>Adenosine. A physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils</article-title>. <source>J. Immunol</source>. <volume>135</volume>, <fpage>1366</fpage>–<lpage>1371</lpage><pub-id pub-id-type="pmid">2989364</pub-id></mixed-citation>
              </ref>
              <ref id="B15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Csóka</surname><given-names>B.</given-names></name><name><surname>Himer</surname><given-names>L.</given-names></name><name><surname>Selmeczy</surname><given-names>Z.</given-names></name><name><surname>Vizi</surname><given-names>E. S.</given-names></name><name><surname>Pacher</surname><given-names>P.</given-names></name><name><surname>Ledent</surname><given-names>C.</given-names></name><name><surname>Deitch</surname><given-names>E. A.</given-names></name><name><surname>Spolarics</surname><given-names>Z.</given-names></name><name><surname>Németh</surname><given-names>Z. H.</given-names></name><name><surname>Haskó</surname><given-names>G.</given-names></name></person-group> (<year>2008</year>) <article-title>Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function</article-title>. <source>FASEB J</source>. <volume>22</volume>, <fpage>3491</fpage>–<lpage>3499</lpage><pub-id pub-id-type="pmid">18625677</pub-id></mixed-citation>
              </ref>
              <ref id="B16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sitkovsky</surname><given-names>M. V.</given-names></name><name><surname>Ohta</surname><given-names>A.</given-names></name></person-group> (<year>2005</year>) <article-title>The “danger” sensors that STOP the immune response. The A2 adenosine receptors?</article-title>
<source>Trends Immunol</source>. <volume>26</volume>, <fpage>299</fpage>–<lpage>304</lpage><pub-id pub-id-type="pmid">15922945</pub-id></mixed-citation>
              </ref>
              <ref id="B17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trautmann</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>) <article-title>Extracellular ATP in the immune system. More than just a “danger signal”</article-title>. <source>Sci. Signal</source>. <volume>2</volume>, <fpage>pe6</fpage><pub-id pub-id-type="pmid">19193605</pub-id></mixed-citation>
              </ref>
              <ref id="B18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robson</surname><given-names>S. C.</given-names></name><name><surname>Sévigny</surname><given-names>J.</given-names></name><name><surname>Zimmermann</surname><given-names>H.</given-names></name></person-group> (<year>2006</year>) <article-title>The E-NTPDase family of ectonucleotidases. Structure function relationships and pathophysiological significance</article-title>. <source>Purinergic Signal</source>. <volume>2</volume>, <fpage>409</fpage>–<lpage>430</lpage><pub-id pub-id-type="pmid">18404480</pub-id></mixed-citation>
              </ref>
              <ref id="B19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yegutkin</surname><given-names>G. G.</given-names></name></person-group> (<year>2008</year>) <article-title>Nucleotide- and nucleoside-converting ectoenzymes. Important modulators of purinergic signalling cascade</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1783</volume>, <fpage>673</fpage>–<lpage>694</lpage><pub-id pub-id-type="pmid">18302942</pub-id></mixed-citation>
              </ref>
              <ref id="B20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yegutkin</surname><given-names>G. G.</given-names></name><name><surname>Wieringa</surname><given-names>B.</given-names></name><name><surname>Robson</surname><given-names>S. C.</given-names></name><name><surname>Jalkanen</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>) <article-title>Metabolism of circulating ADP in the bloodstream is mediated via integrated actions of soluble adenylate kinase-1 and NTPDase1/CD39 activities</article-title>. <source>FASEB J</source>. <volume>26</volume>, <fpage>3875</fpage>–<lpage>3883</lpage><pub-id pub-id-type="pmid">22637533</pub-id></mixed-citation>
              </ref>
              <ref id="B21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehto</surname><given-names>M. T.</given-names></name><name><surname>Sharom</surname><given-names>F. J.</given-names></name></person-group> (<year>1998</year>) <article-title>Release of the glycosylphosphatidylinositol-anchored enzyme ecto-5′-nucleotidase by phospholipase C. Catalytic activation and modulation by the lipid bilayer</article-title>. <source>Biochem. J</source>. <volume>332</volume>, <fpage>101</fpage>–<lpage>109</lpage><pub-id pub-id-type="pmid">9576857</pub-id></mixed-citation>
              </ref>
              <ref id="B22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strohmeier</surname><given-names>G. R.</given-names></name><name><surname>Lencer</surname><given-names>W. I.</given-names></name><name><surname>Patapoff</surname><given-names>T. W.</given-names></name><name><surname>Thompson</surname><given-names>L. F.</given-names></name><name><surname>Carlson</surname><given-names>S. L.</given-names></name><name><surname>Moe</surname><given-names>S. J.</given-names></name><name><surname>Carnes</surname><given-names>D. K.</given-names></name><name><surname>Mrsny</surname><given-names>R. J.</given-names></name><name><surname>Madara</surname><given-names>J. L.</given-names></name></person-group> (<year>1997</year>) <article-title>Surface expression, polarization, and functional significance of CD73 in human intestinal epithelia</article-title>. <source>J. Clin. Invest</source>. <volume>99</volume>, <fpage>2588</fpage>–<lpage>2601</lpage><pub-id pub-id-type="pmid">9169488</pub-id></mixed-citation>
              </ref>
              <ref id="B23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Low</surname><given-names>M. G.</given-names></name></person-group> (<year>1987</year>) <article-title>Biochemistry of the glycosyl-phosphatidylinositol membrane protein anchors</article-title>. <source>Biochem. J</source>. <volume>244</volume>, <fpage>1</fpage>–<lpage>13</lpage><pub-id pub-id-type="pmid">2959270</pub-id></mixed-citation>
              </ref>
              <ref id="B24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solter</surname><given-names>P. F.</given-names></name><name><surname>Hoffmann</surname><given-names>W. E.</given-names></name></person-group> (<year>1999</year>) <article-title>Solubilization of liver alkaline phosphatase isoenzyme during cholestasis in dogs</article-title>. <source>Am. J. Vet. Res</source>. <volume>60</volume>, <fpage>1010</fpage>–<lpage>1015</lpage><pub-id pub-id-type="pmid">10451214</pub-id></mixed-citation>
              </ref>
              <ref id="B25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molina-Arcas</surname><given-names>M.</given-names></name><name><surname>Casado</surname><given-names>F. J.</given-names></name><name><surname>Pastor-Anglada</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>) <article-title>Nucleoside transporter proteins</article-title>. <source>Curr. Vasc. Pharmacol</source>. <volume>7</volume>, <fpage>426</fpage>–<lpage>434</lpage><pub-id pub-id-type="pmid">19485885</pub-id></mixed-citation>
              </ref>
              <ref id="B26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Meester</surname><given-names>I.</given-names></name><name><surname>Vanham</surname><given-names>G.</given-names></name><name><surname>Kestens</surname><given-names>L.</given-names></name><name><surname>Vanhoof</surname><given-names>G.</given-names></name><name><surname>Bosmans</surname><given-names>E.</given-names></name><name><surname>Gigase</surname><given-names>P.</given-names></name><name><surname>Scharpé</surname><given-names>S.</given-names></name></person-group> (<year>1994</year>) <article-title>Binding of adenosine deaminase to the lymphocyte surface via CD26</article-title>. <source>Eur. J. Immunol</source>. <volume>24</volume>, <fpage>566</fpage>–<lpage>570</lpage><pub-id pub-id-type="pmid">7907293</pub-id></mixed-citation>
              </ref>
              <ref id="B27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrera</surname><given-names>C.</given-names></name><name><surname>Casadó</surname><given-names>V.</given-names></name><name><surname>Ciruela</surname><given-names>F.</given-names></name><name><surname>Schofield</surname><given-names>P.</given-names></name><name><surname>Mallol</surname><given-names>J.</given-names></name><name><surname>Lluis</surname><given-names>C.</given-names></name><name><surname>Franco</surname><given-names>R.</given-names></name></person-group> (<year>2001</year>) <article-title>Adenosine A2B receptors behave as an alternative anchoring protein for cell surface adenosine deaminase in lymphocytes and cultured cells</article-title>. <source>Mol. Pharmacol</source>. <volume>59</volume>, <fpage>127</fpage>–<lpage>134</lpage><pub-id pub-id-type="pmid">11125033</pub-id></mixed-citation>
              </ref>
              <ref id="B28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>O.</given-names></name></person-group> (<year>2007</year>) <article-title>Innate immunity of the newborn. Basic mechanisms and clinical correlates</article-title>. <source>Nat. Rev. Immunol</source>. <volume>7</volume>, <fpage>379</fpage>–<lpage>390</lpage><pub-id pub-id-type="pmid">17457344</pub-id></mixed-citation>
              </ref>
              <ref id="B29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>O.</given-names></name><name><surname>Zarember</surname><given-names>K. A.</given-names></name><name><surname>Roy</surname><given-names>R. M.</given-names></name><name><surname>Cywes</surname><given-names>C.</given-names></name><name><surname>Godowski</surname><given-names>P. J.</given-names></name><name><surname>Wessels</surname><given-names>M. R.</given-names></name></person-group> (<year>2004</year>) <article-title>Selective impairment of TLR-mediated innate immunity in human newborns. Neonatal blood plasma reduces monocyte TNF-α induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848</article-title>. <source>J. Immunol</source>. <volume>173</volume>, <fpage>4627</fpage>–<lpage>4634</lpage><pub-id pub-id-type="pmid">15383597</pub-id></mixed-citation>
              </ref>
              <ref id="B30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>M.</given-names></name><name><surname>Leuridan</surname><given-names>E.</given-names></name><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>De Wit</surname><given-names>D.</given-names></name><name><surname>Willems</surname><given-names>F.</given-names></name><name><surname>Van Damme</surname><given-names>P.</given-names></name><name><surname>Goldman</surname><given-names>M.</given-names></name><name><surname>Goriely</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>) <article-title>Acquisition of adult-like TLR4 and TLR9 responses during the first year of life</article-title>. <source>PLoS One</source>
<volume>5</volume>, <fpage>e10407</fpage><pub-id pub-id-type="pmid">20442853</pub-id></mixed-citation>
              </ref>
              <ref id="B31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willems</surname><given-names>F.</given-names></name><name><surname>Vollstedt</surname><given-names>S.</given-names></name><name><surname>Suter</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>) <article-title>Phenotype and function of neonatal DC</article-title>. <source>Eur. J. Immunol</source>. <volume>39</volume>, <fpage>26</fpage>–<lpage>35</lpage><pub-id pub-id-type="pmid">19137537</pub-id></mixed-citation>
              </ref>
              <ref id="B32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>O.</given-names></name><name><surname>Coughlin</surname><given-names>M.</given-names></name><name><surname>Cronstein</surname><given-names>B. N.</given-names></name><name><surname>Roy</surname><given-names>R. M.</given-names></name><name><surname>Desai</surname><given-names>A.</given-names></name><name><surname>Wessels</surname><given-names>M. R.</given-names></name></person-group> (<year>2006</year>) <article-title>The adenosine system selectively inhibits TLR-mediated TNF-α production in the human newborn</article-title>. <source>J. Immunol</source>. <volume>177</volume>, <fpage>1956</fpage>–<lpage>1966</lpage><pub-id pub-id-type="pmid">16849509</pub-id></mixed-citation>
              </ref>
              <ref id="B33">
                <label>33.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belderbos</surname><given-names>M. E.</given-names></name><name><surname>Levy</surname><given-names>O.</given-names></name><name><surname>Stalpers</surname><given-names>F.</given-names></name><name><surname>Kimpen</surname><given-names>J. L.</given-names></name><name><surname>Meyaard</surname><given-names>L.</given-names></name><name><surname>Bont</surname><given-names>L.</given-names></name></person-group> (<year>2012</year>) <article-title>Neonatal plasma polarizes TLR4-mediated cytokine responses towards low IL-12p70 and high IL-10 production via distinct factors</article-title>. <source>PLoS One</source>
<volume>7</volume>, <fpage>e33419</fpage><pub-id pub-id-type="pmid">22442690</pub-id></mixed-citation>
              </ref>
              <ref id="B34">
                <label>34.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahl</surname><given-names>R.</given-names></name><name><surname>Sergienko</surname><given-names>E. A.</given-names></name><name><surname>Su</surname><given-names>Y.</given-names></name><name><surname>Mostofi</surname><given-names>Y. S.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Simao</surname><given-names>A. M.</given-names></name><name><surname>Narisawa</surname><given-names>S.</given-names></name><name><surname>Brown</surname><given-names>B.</given-names></name><name><surname>Mangravita-Novo</surname><given-names>A.</given-names></name><name><surname>Vicchiarelli</surname><given-names>M.</given-names></name><name><surname>Smith</surname><given-names>L. H.</given-names></name><name><surname>O'Neill</surname><given-names>W. C.</given-names></name><name><surname>Millán</surname><given-names>J. L.</given-names></name><name><surname>Cosford</surname><given-names>N. D.</given-names></name></person-group> (<year>2009</year>) <article-title>Discovery and validation of a series of aryl sulfonamides as selective inhibitors of tissue-nonspecific alkaline phosphatase (TNAP)</article-title>. <source>J. Med. Chem</source>. <volume>52</volume>, <fpage>6919</fpage>–<lpage>6925</lpage><pub-id pub-id-type="pmid">19821572</pub-id></mixed-citation>
              </ref>
              <ref id="B35">
                <label>35.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burl</surname><given-names>S.</given-names></name><name><surname>Townend</surname><given-names>J.</given-names></name><name><surname>Njie-Jobe</surname><given-names>J.</given-names></name><name><surname>Cox</surname><given-names>M.</given-names></name><name><surname>Adetifa</surname><given-names>U. J.</given-names></name><name><surname>Touray</surname><given-names>E.</given-names></name><name><surname>Philbin</surname><given-names>V. J.</given-names></name><name><surname>Mancuso</surname><given-names>C.</given-names></name><name><surname>Kampmann</surname><given-names>B.</given-names></name><name><surname>Whittle</surname><given-names>H.</given-names></name><name><surname>Jaye</surname><given-names>A.</given-names></name><name><surname>Flanagan</surname><given-names>K. L.</given-names></name><name><surname>Levy</surname><given-names>O.</given-names></name></person-group> (<year>2011</year>) <article-title>Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants</article-title>. <source>PLoS One</source>
<volume>6</volume>, <fpage>e18185</fpage><pub-id pub-id-type="pmid">21533209</pub-id></mixed-citation>
              </ref>
              <ref id="B36">
                <label>36.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corbett</surname><given-names>N. P.</given-names></name><name><surname>Blimkie</surname><given-names>D.</given-names></name><name><surname>Ho</surname><given-names>K. C.</given-names></name><name><surname>Cai</surname><given-names>B.</given-names></name><name><surname>Sutherland</surname><given-names>D. P.</given-names></name><name><surname>Kallos</surname><given-names>A.</given-names></name><name><surname>Crabtree</surname><given-names>J.</given-names></name><name><surname>Rein-Weston</surname><given-names>A.</given-names></name><name><surname>Lavoie</surname><given-names>P. M.</given-names></name><name><surname>Turvey</surname><given-names>S. E.</given-names></name><name><surname>Hawkins</surname><given-names>N. R.</given-names></name><name><surname>Self</surname><given-names>S. G.</given-names></name><name><surname>Wilson</surname><given-names>C. B.</given-names></name><name><surname>Hajjar</surname><given-names>A. M.</given-names></name><name><surname>Fortuno</surname><given-names>E. S.</given-names><suffix>3rd</suffix></name><name><surname>Kollmann</surname><given-names>T. R.</given-names></name></person-group> (<year>2010</year>) <article-title>Ontogeny of Toll-like receptor mediated cytokine responses of human blood mononuclear cells</article-title>. <source>PLoS One</source>
<volume>5</volume>, <fpage>e15041</fpage><pub-id pub-id-type="pmid">21152080</pub-id></mixed-citation>
              </ref>
              <ref id="B37">
                <label>37.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nauseef</surname><given-names>W. M.</given-names></name></person-group> (<year>2007</year>) <article-title>Isolation of human neutrophils from venous blood</article-title>. <source>Methods Mol. Biol</source>. <volume>412</volume>, <fpage>15</fpage>–<lpage>20</lpage><pub-id pub-id-type="pmid">18453102</pub-id></mixed-citation>
              </ref>
              <ref id="B38">
                <label>38.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosalki</surname><given-names>S. B.</given-names></name><name><surname>Foo</surname><given-names>A. Y.</given-names></name></person-group> (<year>1984</year>) <article-title>Two new methods for separating and quantifying bone and liver alkaline phosphatase isoenzymes in plasma</article-title>. <source>Clin. Chem</source>. <volume>30</volume>, <fpage>1182</fpage>–<lpage>1186</lpage><pub-id pub-id-type="pmid">6547374</pub-id></mixed-citation>
              </ref>
              <ref id="B39">
                <label>39.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mack</surname><given-names>D.</given-names></name><name><surname>Fischer</surname><given-names>W.</given-names></name><name><surname>Krokotsch</surname><given-names>A.</given-names></name><name><surname>Leopold</surname><given-names>K.</given-names></name><name><surname>Hartmann</surname><given-names>R.</given-names></name><name><surname>Egge</surname><given-names>H.</given-names></name><name><surname>Laufs</surname><given-names>R.</given-names></name></person-group> (<year>1996</year>) <article-title>The intercellular adhesin involved in biofilm accumulation of <italic>Staphylococcus epidermidis</italic> is a linear β-1,6-linked glucosaminoglycan. Purification and structural analysis</article-title>. <source>J. Bacteriol</source>. <volume>178</volume>, <fpage>175</fpage>–<lpage>183</lpage><pub-id pub-id-type="pmid">8550413</pub-id></mixed-citation>
              </ref>
              <ref id="B40">
                <label>40.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coade</surname><given-names>S. B.</given-names></name><name><surname>Pearson</surname><given-names>J. D.</given-names></name></person-group> (<year>1989</year>) <article-title>Metabolism of adenine nucleotides in human blood</article-title>. <source>Circ. Res</source>. <volume>65</volume>, <fpage>531</fpage>–<lpage>537</lpage><pub-id pub-id-type="pmid">2548757</pub-id></mixed-citation>
              </ref>
              <ref id="B41">
                <label>41.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>L. F.</given-names></name><name><surname>Ruedi</surname><given-names>J. M.</given-names></name><name><surname>O'Connor</surname><given-names>R. D.</given-names></name><name><surname>Bastian</surname><given-names>J. F.</given-names></name></person-group> (<year>1986</year>) <article-title>Ecto-5′-nucleotidase expression during human B cell development. An explanation for the heterogeneity in B lymphocyte ecto-5′-nucleotidase activity in patients with hypogammaglobulinemia</article-title>. <source>J. Immunol</source>. <volume>137</volume>, <fpage>2496</fpage>–<lpage>2500</lpage><pub-id pub-id-type="pmid">3020125</pub-id></mixed-citation>
              </ref>
              <ref id="B42">
                <label>42.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schelonka</surname><given-names>R. L.</given-names></name><name><surname>Yoder</surname><given-names>B. A.</given-names></name><name><surname>desJardins</surname><given-names>S. E.</given-names></name><name><surname>Hall</surname><given-names>R. B.</given-names></name><name><surname>Butler</surname><given-names>J.</given-names></name></person-group> (<year>1994</year>) <article-title>Peripheral leukocyte count and leukocyte indexes in healthy newborn term infants</article-title>. <source>J. Pediatr</source>. <volume>125</volume>, <fpage>603</fpage>–<lpage>606</lpage><pub-id pub-id-type="pmid">7931882</pub-id></mixed-citation>
              </ref>
              <ref id="B43">
                <label>43.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banz</surname><given-names>Y.</given-names></name><name><surname>Beldi</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Atkinson</surname><given-names>B.</given-names></name><name><surname>Usheva</surname><given-names>A.</given-names></name><name><surname>Robson</surname><given-names>S. C.</given-names></name></person-group> (<year>2008</year>) <article-title>CD39 is incorporated into plasma microparticles where it maintains functional properties and impacts endothelial activation</article-title>. <source>Br. J. Haematol</source>. <volume>142</volume>, <fpage>627</fpage>–<lpage>637</lpage><pub-id pub-id-type="pmid">18537971</pub-id></mixed-citation>
              </ref>
              <ref id="B44">
                <label>44.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sergienko</surname><given-names>E.</given-names></name><name><surname>Su</surname><given-names>Y.</given-names></name><name><surname>Chan</surname><given-names>X.</given-names></name><name><surname>Brown</surname><given-names>B.</given-names></name><name><surname>Hurder</surname><given-names>A.</given-names></name><name><surname>Narisawa</surname><given-names>S.</given-names></name><name><surname>Millán</surname><given-names>J. L.</given-names></name></person-group> (<year>2009</year>) <article-title>Identification and characterization of novel tissue-nonspecific alkaline phosphatase inhibitors with diverse modes of action</article-title>. <source>J. Biomol. Screen</source>
<volume>14</volume>, <fpage>824</fpage>–<lpage>837</lpage><pub-id pub-id-type="pmid">19556612</pub-id></mixed-citation>
              </ref>
              <ref id="B45">
                <label>45.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Millán</surname><given-names>J. L.</given-names></name></person-group> (<year>2006</year>) <source>Mammalian Alkaline Phosphatases: From Biology to Applications in Medicine and Biotechnology</source>, <publisher-name>Wiley-VCH</publisher-name>, <publisher-loc>Weinheim, Germany</publisher-loc></mixed-citation>
              </ref>
              <ref id="B46">
                <label>46.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lockitch</surname><given-names>G.</given-names></name><name><surname>Halstead</surname><given-names>A. C.</given-names></name><name><surname>Albersheim</surname><given-names>S.</given-names></name><name><surname>MacCallum</surname><given-names>C.</given-names></name><name><surname>Quigley</surname><given-names>G.</given-names></name></person-group> (<year>1988</year>) <article-title>Age- and sex-specific pediatric reference intervals for biochemistry analytes as measured with the Ektachem-700 analyzer</article-title>. <source>Clin. Chem</source>. <volume>34</volume>, <fpage>1622</fpage>–<lpage>1625</lpage><pub-id pub-id-type="pmid">3402068</pub-id></mixed-citation>
              </ref>
              <ref id="B47">
                <label>47.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zavialov</surname><given-names>A. V.</given-names></name><name><surname>Engström</surname><given-names>A.</given-names></name></person-group> (<year>2005</year>) <article-title>Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity</article-title>. <source>Biochem. J</source>. <volume>391</volume>, <fpage>51</fpage>–<lpage>57</lpage><pub-id pub-id-type="pmid">15926889</pub-id></mixed-citation>
              </ref>
              <ref id="B48">
                <label>48.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zavialov</surname><given-names>A. V.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Spillmann</surname><given-names>D.</given-names></name><name><surname>Lauvau</surname><given-names>G.</given-names></name></person-group> (<year>2010</year>) <article-title>Structural basis for the growth factor activity of human adenosine deaminase ADA2</article-title>. <source>J. Biol. Chem</source>. <volume>285</volume>, <fpage>12367</fpage>–<lpage>12377</lpage><pub-id pub-id-type="pmid">20147294</pub-id></mixed-citation>
              </ref>
              <ref id="B49">
                <label>49.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strunk</surname><given-names>T.</given-names></name><name><surname>Power Coombs</surname><given-names>M. R.</given-names></name><name><surname>Currie</surname><given-names>A. J.</given-names></name><name><surname>Richmond</surname><given-names>P.</given-names></name><name><surname>Golenbock</surname><given-names>D. T.</given-names></name><name><surname>Stoler-Barak</surname><given-names>L.</given-names></name><name><surname>Gallington</surname><given-names>L. C.</given-names></name><name><surname>Otto</surname><given-names>M.</given-names></name><name><surname>Burgner</surname><given-names>D.</given-names></name><name><surname>Levy</surname><given-names>O.</given-names></name></person-group> (<year>2010</year>) <article-title>TLR2 mediates recognition of live <italic>Staphylococcus epidermidis</italic> and clearance of bacteremia</article-title>. <source>PLoS One</source>
<volume>5</volume>, <fpage>e10111</fpage><pub-id pub-id-type="pmid">20404927</pub-id></mixed-citation>
              </ref>
              <ref id="B50">
                <label>50.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thammavongsa</surname><given-names>V.</given-names></name><name><surname>Kern</surname><given-names>J. W.</given-names></name><name><surname>Missiakas</surname><given-names>D. M.</given-names></name><name><surname>Schneewind</surname><given-names>O.</given-names></name></person-group> (<year>2009</year>) <article-title><italic>Staphylococcus aureus</italic> synthesizes adenosine to escape host immune responses</article-title>. <source>J. Exp. Med</source>. <volume>206</volume>, <fpage>2417</fpage>–<lpage>2427</lpage><pub-id pub-id-type="pmid">19808256</pub-id></mixed-citation>
              </ref>
              <ref id="B51">
                <label>51.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deaglio</surname><given-names>S.</given-names></name><name><surname>Robson</surname><given-names>S. C.</given-names></name></person-group> (<year>2011</year>) <article-title>Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity</article-title>. <source>Adv. Pharmacol</source>. <volume>61</volume>, <fpage>301</fpage>–<lpage>332</lpage><pub-id pub-id-type="pmid">21586363</pub-id></mixed-citation>
              </ref>
              <ref id="B52">
                <label>52.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Proytcheva</surname><given-names>M. A.</given-names></name></person-group> (<year>2011</year>) <source>Diagnostic Pediatric Hematopathology</source>, pp. <fpage>5</fpage>–<lpage>20</lpage>, <publisher-name>Cambridge University Press</publisher-name>, <publisher-loc>Cambridge, UK</publisher-loc></mixed-citation>
              </ref>
              <ref id="B53">
                <label>53.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Junger</surname><given-names>W. G.</given-names></name></person-group> (<year>2011</year>) <article-title>Immune cell regulation by autocrine purinergic signalling</article-title>. <source>Nat. Rev. Immunol</source>. <volume>11</volume>, <fpage>201</fpage>–<lpage>212</lpage><pub-id pub-id-type="pmid">21331080</pub-id></mixed-citation>
              </ref>
              <ref id="B54">
                <label>54.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crofton</surname><given-names>P. M.</given-names></name></person-group> (<year>1987</year>) <article-title>Properties of alkaline phosphatase isoenzymes in plasma of preterm and term neonates</article-title>. <source>Clin. Chem</source>. <volume>33</volume>, <fpage>1778</fpage>–<lpage>1782</lpage><pub-id pub-id-type="pmid">3665029</pub-id></mixed-citation>
              </ref>
              <ref id="B55">
                <label>55.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Born</surname><given-names>G. V.</given-names></name><name><surname>Kratzer</surname><given-names>M. A.</given-names></name></person-group> (<year>1984</year>) <article-title>Source and concentration of extracellular adenosine triphosphate during haemostasis in rats, rabbits and man</article-title>. <source>J. Physiol</source>. <volume>354</volume>, <fpage>419</fpage>–<lpage>429</lpage><pub-id pub-id-type="pmid">6481640</pub-id></mixed-citation>
              </ref>
              <ref id="B56">
                <label>56.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellegatti</surname><given-names>P.</given-names></name><name><surname>Raffaghello</surname><given-names>L.</given-names></name><name><surname>Bianchi</surname><given-names>G.</given-names></name><name><surname>Piccardi</surname><given-names>F.</given-names></name><name><surname>Pistoia</surname><given-names>V.</given-names></name><name><surname>Di Virgilio</surname><given-names>F.</given-names></name></person-group> (<year>2008</year>) <article-title>Increased level of extracellular ATP at tumor sites. <italic>In vivo</italic> imaging with plasma membrane luciferase</article-title>. <source>PLoS One</source>
<volume>3</volume>, <fpage>e2599</fpage><pub-id pub-id-type="pmid">18612415</pub-id></mixed-citation>
              </ref>
              <ref id="B57">
                <label>57.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coutinho-Silva</surname><given-names>R.</given-names></name><name><surname>Corrêa</surname><given-names>G.</given-names></name><name><surname>Sater</surname><given-names>A. A.</given-names></name><name><surname>Ojcius</surname><given-names>D. M.</given-names></name></person-group> (<year>2009</year>) <article-title>The P2X<sub>7</sub> receptor and intracellular pathogens. A continuing struggle</article-title>. <source>Purinergic Signal</source>. <volume>5</volume>, <fpage>197</fpage>–<lpage>204</lpage><pub-id pub-id-type="pmid">19214779</pub-id></mixed-citation>
              </ref>
              <ref id="B58">
                <label>58.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tschopp</surname><given-names>J.</given-names></name><name><surname>Schroder</surname><given-names>K.</given-names></name></person-group> (<year>2010</year>) <article-title>NLRP3 inflammasome activation. The convergence of multiple signalling pathways on ROS production?</article-title>
<source>Nat. Rev. Immunol</source>. <volume>10</volume>, <fpage>210</fpage>–<lpage>215</lpage><pub-id pub-id-type="pmid">20168318</pub-id></mixed-citation>
              </ref>
              <ref id="B59">
                <label>59.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedata</surname><given-names>F.</given-names></name><name><surname>Corsi</surname><given-names>C.</given-names></name><name><surname>Melani</surname><given-names>A.</given-names></name><name><surname>Bordoni</surname><given-names>F.</given-names></name><name><surname>Latini</surname><given-names>S.</given-names></name></person-group> (<year>2001</year>) <article-title>Adenosine extracellular brain concentrations and role of A2A receptors in ischemia</article-title>. <source>Ann. N.Y. Acad. Sci</source>. <volume>939</volume>, <fpage>74</fpage>–<lpage>84</lpage><pub-id pub-id-type="pmid">11462806</pub-id></mixed-citation>
              </ref>
              <ref id="B60">
                <label>60.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagberg</surname><given-names>H.</given-names></name><name><surname>Andersson</surname><given-names>P.</given-names></name><name><surname>Lacarewicz</surname><given-names>J.</given-names></name><name><surname>Jacobson</surname><given-names>I.</given-names></name><name><surname>Butcher</surname><given-names>S.</given-names></name><name><surname>Sandberg</surname><given-names>M.</given-names></name></person-group> (<year>1987</year>) <article-title>Extracellular adenosine, inosine, hypoxanthine, and xanthine in relation to tissue nucleotides and purines in rat striatum during transient ischemia</article-title>. <source>J. Neurochem</source>. <volume>49</volume>, <fpage>227</fpage>–<lpage>231</lpage><pub-id pub-id-type="pmid">3585332</pub-id></mixed-citation>
              </ref>
              <ref id="B61">
                <label>61.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angelone</surname><given-names>D. F.</given-names></name><name><surname>Wessels</surname><given-names>M. R.</given-names></name><name><surname>Coughlin</surname><given-names>M.</given-names></name><name><surname>Suter</surname><given-names>E. E.</given-names></name><name><surname>Valentini</surname><given-names>P.</given-names></name><name><surname>Kalish</surname><given-names>L. A.</given-names></name><name><surname>Levy</surname><given-names>O.</given-names></name></person-group> (<year>2006</year>) <article-title>Innate immunity of the human newborn is polarized toward a high ratio of IL-6/TNF-α production <italic>in vitro</italic> and <italic>in vivo</italic></article-title>. <source>Pediatr. Res</source>. <volume>60</volume>, <fpage>205</fpage>–<lpage>209</lpage><pub-id pub-id-type="pmid">16864705</pub-id></mixed-citation>
              </ref>
              <ref id="B62">
                <label>62.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kollmann</surname><given-names>T. R.</given-names></name><name><surname>Crabtree</surname><given-names>J.</given-names></name><name><surname>Rein-Weston</surname><given-names>A.</given-names></name><name><surname>Blimkie</surname><given-names>D.</given-names></name><name><surname>Thommai</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>X. Y.</given-names></name><name><surname>Lavoie</surname><given-names>P. M.</given-names></name><name><surname>Furlong</surname><given-names>J.</given-names></name><name><surname>Fortuno</surname><given-names>E. S.</given-names><suffix>3rd</suffix></name><name><surname>Hajjar</surname><given-names>A. M.</given-names></name><name><surname>Hawkins</surname><given-names>N. R.</given-names></name><name><surname>Self</surname><given-names>S. G.</given-names></name><name><surname>Wilson</surname><given-names>C. B.</given-names></name></person-group> (<year>2009</year>) <article-title>Neonatal innate TLR-mediated responses are distinct from those of adults</article-title>. <source>J. Immunol</source>. <volume>183</volume>, <fpage>7150</fpage>–<lpage>7160</lpage><pub-id pub-id-type="pmid">19917677</pub-id></mixed-citation>
              </ref>
              <ref id="B63">
                <label>63.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirschhorn</surname><given-names>R.</given-names></name><name><surname>Beratis</surname><given-names>N. G.</given-names></name></person-group> (<year>1973</year>) <article-title>Letter. Severe combined immunodeficiency and adenosine-deaminase deficiency</article-title>. <source>Lancet</source>
<volume>2</volume>, <fpage>1217</fpage>–<lpage>1218</lpage><pub-id pub-id-type="pmid">4127604</pub-id></mixed-citation>
              </ref>
              <ref id="B64">
                <label>64.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Remington</surname><given-names>J. S.</given-names></name><name><surname>Klein</surname><given-names>J. O.</given-names></name><name><surname>Wilson</surname><given-names>C. B.</given-names></name><name><surname>Nizet</surname><given-names>V.</given-names></name><name><surname>Maldonado</surname><given-names>Y.</given-names></name></person-group> (<year>2011</year>) <source>Infectious Diseases of the Fetus and Newborn Infant</source>, pp. <fpage>80</fpage>–<lpage>191</lpage>, <edition>7th Ed.</edition>, <publisher-name>Elsevier</publisher-name>, <publisher-loc>Philadelphia</publisher-loc></mixed-citation>
              </ref>
              <ref id="B65">
                <label>65.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sussman</surname><given-names>H. H.</given-names></name><name><surname>Bowman</surname><given-names>M.</given-names></name><name><surname>Lewis</surname><given-names>J. L.</given-names><suffix>Jr.</suffix></name></person-group> (<year>1968</year>) <article-title>Placental alkaline phosphatase in maternal serum during normal and abnormal pregnancy</article-title>. <source>Nature</source>
<volume>218</volume>, <fpage>359</fpage>–<lpage>360</lpage><pub-id pub-id-type="pmid">5649676</pub-id></mixed-citation>
              </ref>
              <ref id="B66">
                <label>66.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoneyama</surname><given-names>Y.</given-names></name><name><surname>Suzuki</surname><given-names>S.</given-names></name><name><surname>Sawa</surname><given-names>R.</given-names></name><name><surname>Otsubo</surname><given-names>Y.</given-names></name><name><surname>Power</surname><given-names>G. G.</given-names></name><name><surname>Araki</surname><given-names>T.</given-names></name></person-group> (<year>2000</year>) <article-title>Plasma adenosine levels increase in women with normal pregnancies</article-title>. <source>Am. J. Obstet. Gynecol</source>. <volume>182</volume>, <fpage>1200</fpage>–<lpage>1203</lpage><pub-id pub-id-type="pmid">10819858</pub-id></mixed-citation>
              </ref>
              <ref id="B67">
                <label>67.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoneyama</surname><given-names>Y.</given-names></name><name><surname>Suzuki</surname><given-names>S.</given-names></name><name><surname>Sawa</surname><given-names>R.</given-names></name><name><surname>Otsubo</surname><given-names>Y.</given-names></name><name><surname>Miura</surname><given-names>A.</given-names></name><name><surname>Kuwabara</surname><given-names>Y.</given-names></name><name><surname>Ishino</surname><given-names>H.</given-names></name><name><surname>Kiyokawa</surname><given-names>Y.</given-names></name><name><surname>Doi</surname><given-names>D.</given-names></name><name><surname>Yoneyama</surname><given-names>K.</given-names></name><name><surname>Araki</surname><given-names>T.</given-names></name></person-group> (<year>2003</year>) <article-title>Serum adenosine deaminase activity and its isoenzyme pattern in women with normal pregnancies</article-title>. <source>Arch. Gynecol. Obstet</source>. <volume>267</volume>, <fpage>205</fpage>–<lpage>207</lpage><pub-id pub-id-type="pmid">12592419</pub-id></mixed-citation>
              </ref>
              <ref id="B68">
                <label>68.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamieson</surname><given-names>D. J.</given-names></name><name><surname>Theiler</surname><given-names>R. N.</given-names></name><name><surname>Rasmussen</surname><given-names>S. A.</given-names></name></person-group> (<year>2006</year>) <article-title>Emerging infections and pregnancy</article-title>. <source>Emerg. Infect. Dis</source>. <volume>12</volume>, <fpage>1638</fpage>–<lpage>1643</lpage><pub-id pub-id-type="pmid">17283611</pub-id></mixed-citation>
              </ref>
              <ref id="B69">
                <label>69.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weetman</surname><given-names>A. P.</given-names></name></person-group> (<year>1999</year>) <article-title>The immunology of pregnancy</article-title>. <source>Thyroid</source>
<volume>9</volume>, <fpage>643</fpage>–<lpage>646</lpage><pub-id pub-id-type="pmid">10447007</pub-id></mixed-citation>
              </ref>
              <ref id="B70">
                <label>70.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Z. G.</given-names></name><name><surname>Ye</surname><given-names>K.</given-names></name><name><surname>Göblyös</surname><given-names>A.</given-names></name><name><surname>Ijzerman</surname><given-names>A. P.</given-names></name><name><surname>Jacobson</surname><given-names>K. A.</given-names></name></person-group> (<year>2008</year>) <article-title>Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000</article-title>. <source>BMC Pharmacol</source>. <volume>8</volume>, <fpage>20</fpage><pub-id pub-id-type="pmid">19077268</pub-id></mixed-citation>
              </ref>
              <ref id="B71">
                <label>71.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schön</surname><given-names>M. P.</given-names></name><name><surname>Schön</surname><given-names>M.</given-names></name></person-group> (<year>2007</year>) <article-title>Imiquimod. Mode of action</article-title>. <source>Br. J. Dermatol</source>. <volume>157</volume>, <fpage>8</fpage>–<lpage>13</lpage><pub-id pub-id-type="pmid">18067624</pub-id></mixed-citation>
              </ref>
              <ref id="B72">
                <label>72.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schön</surname><given-names>M. P.</given-names></name><name><surname>Schön</surname><given-names>M.</given-names></name><name><surname>Klotz</surname><given-names>K. N.</given-names></name></person-group> (<year>2006</year>) <article-title>The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion</article-title>. <source>J. Invest. Dermatol</source>. <volume>126</volume>, <fpage>1338</fpage>–<lpage>1347</lpage><pub-id pub-id-type="pmid">16575388</pub-id></mixed-citation>
              </ref>
              <ref id="B73">
                <label>73.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philbin</surname><given-names>V. J.</given-names></name><name><surname>Dowling</surname><given-names>D. J.</given-names></name><name><surname>Gallington</surname><given-names>L. C.</given-names></name><name><surname>Cortés</surname><given-names>G.</given-names></name><name><surname>Tan</surname><given-names>Z.</given-names></name><name><surname>Suter</surname><given-names>E. E.</given-names></name><name><surname>Chi</surname><given-names>K. W.</given-names></name><name><surname>Shuckett</surname><given-names>A.</given-names></name><name><surname>Stoler-Barak</surname><given-names>L.</given-names></name><name><surname>Tomai</surname><given-names>M.</given-names></name><name><surname>Miller</surname><given-names>R. L.</given-names></name><name><surname>Mansfield</surname><given-names>K.</given-names></name><name><surname>Levy</surname><given-names>O.</given-names></name></person-group> (<year>2012</year>) <article-title>Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways</article-title>. <source>J. Allergy Clin. Immunol</source>. <volume>130</volume>, <fpage>195</fpage>–<lpage>204.e9</lpage><pub-id pub-id-type="pmid">22521247</pub-id></mixed-citation>
              </ref>
              <ref id="B74">
                <label>74.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wynn</surname><given-names>J. L.</given-names></name><name><surname>Scumpia</surname><given-names>P. O.</given-names></name><name><surname>Winfield</surname><given-names>R. D.</given-names></name><name><surname>Delano</surname><given-names>M. J.</given-names></name><name><surname>Kelly-Scumpia</surname><given-names>K.</given-names></name><name><surname>Barker</surname><given-names>T.</given-names></name><name><surname>Ungaro</surname><given-names>R.</given-names></name><name><surname>Levy</surname><given-names>O.</given-names></name><name><surname>Moldawer</surname><given-names>L. L.</given-names></name></person-group> (<year>2008</year>) <article-title>Defective innate immunity predisposes murine neonates to poor sepsis outcome but is reversed by TLR agonists</article-title>. <source>Blood</source>
<volume>112</volume>, <fpage>1750</fpage>–<lpage>1758</lpage><pub-id pub-id-type="pmid">18591384</pub-id></mixed-citation>
              </ref>
              <ref id="B75">
                <label>75.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Power Coombs</surname><given-names>M. R.</given-names></name><name><surname>Belderbos</surname><given-names>M. E.</given-names></name><name><surname>Gallington</surname><given-names>L. C.</given-names></name><name><surname>Bont</surname><given-names>L.</given-names></name><name><surname>Levy</surname><given-names>O.</given-names></name></person-group> (<year>2011</year>) <article-title>Adenosine modulates Toll-like receptor function: basic mechanisms and translational opportunities</article-title>. <source>Expert Rev. Anti Infect. Ther</source>. <volume>9</volume>, <fpage>261</fpage>–<lpage>269</lpage><pub-id pub-id-type="pmid">21342073</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
